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Abstract 
This study provides information regarding birth-giving in women with multiple 
sclerosis (MS).  
MS is a common disease in the western world and causes disability in young adults 
and, like most immune mediated diseases, affects women more commonly than men. 
The number of births given by women with MS has increased during the last 30 
years, and clinicians often encounter these women’s concerns about pregnancy-
related issues. There are a few studies on the possible effects of MS on the pregnancy 
and the newborn, but so far no serious adverse effects have been shown. (Mueller et 
al. 2002;Poser & Poser 1983;Worthington et al. 1994) However, a diagnosis of MS is 
linked to more frequent operative deliveries. (Davis & Maslow 1992)   
We have evaluated the influence of MS on pregnancy, delivery and birth outcome in 
a large historical cohort. Our study illustrated an overall good outcome for pregnancy 
and birth in MS women, with no increase in adverse birth effects. However, a 
diagnosis of MS reduced neonatal birth weight. This was not due to an increased 
smoking rate among pregnant MS women. MS also increased the duration of the 
second stage of labor and increased the need for induction and operative intervention 
during birth. The increased rate of planned caesarean section might be justified, since 
we found that forceps and vacuum extraction occurred with high frequency despite 
the increased planned caesarean section rate in MS women compared to the 
references. Our results indicate that health professionals should discuss potential 
problems and their possible importance for delivery with each pregnant MS woman. 
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Introduction 
Abbreviations 
BMI Body mass index 
CIS Clinically isolated syndrome 
CNS Central nervous system 
CSF Cerebrospinal fluid 
EDSS Kurtzke’s Expanded Disability Status Scale 
HLA Human leucocyte antigen 
ICD-8/ ICD-10 International Classification of Diseases version 8 and 10 
IFN Interferon 
IL Interleukin  
IVIG Intravenous immunoglobulin 
LBW Low birth weight (<2500g) 
MBRN Medical Birth Registry of Norway 
MRI Magnetic resonance imaging 
MS Multiple sclerosis 
NK Natural killer 
PPMS Primary progressive MS 
PRIMS The Pregnancy in Multiple Sclerosis, a European 
multicenter, prospective, observational study 
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PRISMS Prevention of Relapses and Disability by Interferon β-1a 
Subcutaneously in Multiple Sclerosis Study group 
RRMS Relapsing remitting MS 
SGA Small for gestational age 
SLE Systemic lupus erythematosus 
SPMS Secondary progressive multiple sclerosis 
SPSS Statistical Package for the Social Sciences 
UVB Ultraviolet-B (sunlight radiation 290-315nm) 
VER Visual evoked response  
 
Definitions 
Perinatal mortality All fetal deaths after 16 weeks (12 weeks after 1998) of 
pregnancy and deaths up to 7 days after birth 
Small for gestational age Birth weight below the 10th percentile at the attained 
gestational age according to standards for birth weight by 
gestational age  
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Multiple sclerosis  
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the 
central nervous system (CNS). The disease is one of the common causes of disability 
in young adults, and affects 1:1000 in the western world, and about 2.5 million 
people worldwide. (Compston & Coles 2002) In Norway the prevalence seems to be 
relatively equally distributed (150/100,000), but probably with somewhat fewer 
patients in the northern parts of the country. (Dahl et al. 2004;Gronlie et al. 
2000;Grytten et al. 2006;Torkildsen et al. 2007) The Norwegian MS population is 
estimated to include about 7000 people, with approximately 300 new cases per year. 
(Torkildsen et al. 2007)   
Clinical subtypes 
A relapsing remitting disease (RRMS) affects around 85 % of the patients, 
characterized by repeated attacks (relapses) of neurological dysfunction followed by 
remission. (Confavreux & Vukusic 2006) Within 25 years of disease duration the 
majority (90 %) of patients with RRMS will develop a secondary progressive MS 
(SPMS), (Weinshenker et al. 1989a) characterized by increasing permanent 
neurological disability. Some patients that have developed SPMS also keep having 
distinct relapses superimposed on the progressive course over a variable period of 
time. A primary progressive form of MS (PPMS) affects 15 % of the patients, with a 
steady decline in neurological function without remission of symptoms. However, 
some of the patients in this group have clinical acute relapses superimposed on the 
steady decline in neurological function. (Confavreux & Vukusic 2006) Despite 
different clinical patterns and the fact that the disability progression varies greatly, 
MS is considered to be one distinct disease, but with different clinical phenotypes. 
(Confavreux & Compston 2006) 
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Pathophysiology and clinical symptoms 
MS is characterised by inflammation, demyelination and primary or secondary axonal 
degeneration. (Trapp et al. 1998) Oligodendrocytes, responsible for synthesising and 
maintaining the myelin sheath of axons in the CNS, are the target of the immunologic 
attack. The attack is dominated by T-cells and activated macrophages or microglia. 
The inflammation is thought to be mediated by a T-helper cell specific reaction to 
myelin, but other immune cells are also at play. (McFarland & Martin 2007) On this 
pathological background two different features are seen in the CNS, the focal 
demyelinated plaques and the diffuse global brain injury. The demyelinated plaques 
are characterised by primary demyelination and astrocytic scarring. This pattern 
dominates early in the relapsing disease course. The diffuse brain injury develops 
through a slowly progressive accumulation of inflammation resulting in diffuse tissue 
damage and brain atrophy, which dominates in the later stage of the disease. The 
process progresses to a state with chronic multifocal sclerotic plaques. (Miller 2004) 
Although the inflammation has a typical pattern of distribution, all parts of the CNS 
can be affected and the clinical course is rather unpredictable.  
Common clinical symptoms are paresis and spasticity, sensory symptoms including 
numbness, paresthesias and pain, brainstem and cerebellar symptoms including 
diplopia, dysarthria and ataxia, as well as visual symptoms (optic neuritis), bladder- 
and bowel dysfunction and cognitive changes. There is a higher percentage of optic 
neuritis and diplopia as presenting symptoms in patients with early onset of MS (<30 
years) and of motor disturbances in patients with late onset (>39 years). 
(Weinshenker et al. 1989a) Longitudinal studies on MS cohorts, estimating time from 
onset to disability milestones, have given valuable knowledge on the natural history 
of MS. Median time from disease onset to reaching a disability level when one needs 
a walking-aid is about 20 years. (Confavreux et al. 2003;Myhr et al. 2001) Life 
expectancy for MS patients is reduced by up to 10 years compared to the general 
population. (Bronnum-Hansen et al. 2004)  
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Diagnosis 
There is no pathognomonic test for MS, and the patient history is essential for the 
diagnosis of MS. Due to the inflammatory process, the MS symptoms emerge sub-
acute within hours and days, and lasts for >24 hours and up to 4-6 weeks, before full 
or partial remission. The diagnosis has traditionally been based on clinical features 
alone with disseminated disease in both time (≥ 2 attacks) and space (≥ 2 lesions in 
the CNS). However in 1983, the Poser criteria (Poser et al. 1983) included both 
clinical and paraclinical investigations as it allowed clinical evidence for the disease 
to be replaced by laboratory abnormalities at the second site within the CNS to 
diagnose a clinically definite MS. Imaging, electrophysiology (especially visually 
evoked response, VER) and cerebrospinal fluid (CSF) examinations (oligoclonal IgG 
bands) were used as supplement when the clinical criteria were not met. In 2001, new 
extensive criteria for diagnosing MS were developed by an International Panel, the so 
called McDonald criteria. (McDonald et al. 2001) The main change was inclusion of 
magnetic resonance imaging (MRI) features for defining dissemination of the disease 
in both time and space. The McDonald criteria were later reviewed in 2005, (Polman 
et al. 2005b) focusing on MRI criteria for dissemination in space and time (when a 
relapsing onset) and in the diagnostic criteria for patients with a slowly progressive 
syndrome (PPMS) (Table 1 and 2).  
A high sensitivity of an early diagnosis of MS, with an acceptable level of specificity 
is important since early initiation of treatment has been found to prevent the 
development of disability.(Kappos et al. 2007) Since a high sensitivity of MS to a 
certain degree goes at the expense of the specificity, evaluating possible differential 
diagnoses is important. Typical differential diagnoses of MS are acute disseminated 
encephalomyelitis, infections, and inflammatory disorders such as SLE, sarcoidosis, 
neuromyelitis optica and malignant disease in young as well as vascular diseases at 
older onset patients. (Garcia & Blasco 2007) 
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Table 1 MRI criteria to demonstrate CNS lesions disseminated in space and time suggestive of 
MS 
MRI evidence for dissemination in space - three of the following:  
 a) ≥ 1 gadolinium-enhancing lesion or nine T2 hyperintense lesions if there is no gadolinium 
enhancing lesion 
b) ≥ 1 infratentorial lesion 
c) ≥ 1 juxtacortical lesion 
d) ≥ 3 periventricular lesions 
 
NOTE: A spinal cord lesion can be considered equivalent to a brain infratentorial lesion, an 
enhancing spinal cord lesion is considered to be equivalent to an enhancing brain lesion, and 
individual spinal cord lesions can contribute together with individual brain lesions to reach the 
required number of T2 lesions. 
 
MRI evidence for dissemination in time - one of the following: 
 a) Detection of gadolinium enhancement at least 3 months after the onset of the initial 
clinical event, if not at the site corresponding to the initial event 
b) Detection of a new T2 lesion if it appears at any time compared with a reference scan 
done at least 30 days after the onset of the initial clinical event 
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Table 2 Revised McDonald Diagnostic Criteria for Multiple Sclerosis 
Clinical Presentation 
Clinical attacks Clinical lesions 
 
Additional Data Needed for MS Diagnosis 
 
≥ 2 
 
≥ 2 
None 
• But paraclinical tests (MRI, CSF) should be done to 
exclude other diagnoses. If these tests are negative, 
extreme caution needs to be taken before making a 
diagnosis of MS.  
 
 
≥ 2 
 
1 
 
Dissemination in space, demonstrated by: 
• MRI or 
• Two or more MRI-detected lesions consistent with 
MS plus positive CSF or 
• Await further clinical attack implicating a different site 
 
 
1 
 
≥ 2 
 
Dissemination in time, demonstrated by: 
• MRI or 
• Second clinical attack 
 
1 1 
(monosymptomatic presentation; 
clinically isolated syndrome - CIS) 
Dissemination in space, demonstrated by: 
• MRI or 
• Two or more MRI-detected lesions consistent with 
MS plus positive CSF and 
 
• Dissemination in time, demonstrated by: 
• MRI or 
• Second clinical attack 
 
Insidious neurological progression  
suggestive of MS (PPMS) 
 
One year of disease progression (retrospectively or 
prospectively determined) and two of the following: 
a) Positive brain MRI (nine T2 lesions or four or more 
T2 lesions with positive VER) 
b) Positive spinal cord MRI (two focal T2 lesions) 
c) Positive CSF 
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Aetiology 
MS is regarded as an immune-mediated disorder resulting from complex interactions 
between multiple genetic and environmental factors. (Kantarci & Wingerchuk 2006) 
A high monozygotic (25-30 %) versus dizygotic (3-5 %) concordance rate in twin 
studies reflects the strength of genetic factors relative to environmental factors. 
(Ebers 2005) MS is 20-40 times more common in first-degree relatives of MS 
patients than in the general population. (Weinshenker 1996) The search for candidate 
genes has shown an association between human leukocyte antigen (HLA)-
DRB1*1501 (6p21) and MS, confirmed in a large genetic linkage study in families of 
Northern European descent. (Sawcer et al. 2005) Recently, two new gene 
associations, with interleukin (IL)7R (5p13) and IL2R (10p15), (Hafler et al. 
2007;Lundmark et al. 2007) were identified.  
Since the monozygotic twin concordance rate is (only) 25-30 % and the incidence 
and prevalence varies according to time and geography, environmental factors in the 
aetiology of MS are likely. The sequence of events that initiates the disease is largely 
unknown, since it is still not elucidated which antigen is recognised by the immune 
system or if the local immune response is a primary or secondary event. It seems, 
however, that the pathological process starts several years before the clinical 
symptoms emerge, possibly already during childhood. The susceptibility to 
environmental factors in childhood that can alter the risk of developing MS is 
supported by migration studies. Migration from low to high incidence areas before 
the age of 15 increases the risk of MS, compared to migration after the age of 15. 
(Cabre 2007;Dean & Elian 1997) The correlation of different microbial agents in 
childhood to later development of MS, have for all investigated viruses been 
contradictory. (Compston & Confavreux 2006) One strong exception is the Epstein-
Barr virus in the herpes virus family. The MS risk is around 10 times greater among 
individuals who experienced an undiagnosed Epstein-Barr virus infection in 
childhood, and at least 20-fold greater among individuals who developed 
mononucleosis, compared to individuals not infected. (Ascherio & Munger 2007a) A 
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recent investigation on post-mortem MS brains illustrated Epstein-Barr virus markers 
of infection found in nearly all cases. (Serafini et al. 2007) How the virus is 
associated with the initiation of MS is not known, but the leading hypothesis is that 
the immune response to Epstein-Barr virus infection cross-reacts with myelin 
antigens.  
Since the frequency of MS is found to increase with increasing latitude worldwide – 
even if the difference is starting to diminish, (Ascherio & Munger 2007b) exposure to 
sunlight (UVB radiation) and a corresponding vitamin D synthesis have been 
suggested to influence MS risk. Total vitamin D intake at baseline in two large 
cohorts of US nurses was found inversely associated with the risk of MS. (Munger et 
al. 2004) In a prospective, nested case-control study among US military personnel, it 
was found that high circulating levels of vitamin D were associated with lower risk of 
multiple sclerosis. (Munger et al. 2006) Vitamin D regulates tissue-specific immune 
responses. (Hayes et al. 2003) However, the underlying mechanisms in the MS 
pathogenesis are still under investigation.  
Another non-infectious environmental factor found associated with MS is smoking. 
(Ghadirian et al. 2001) In a Norwegian survey of the general population in Hordaland 
County, the risk of MS was higher among smokers than among never-smokers. (Riise 
et al. 2003) A positive correlation between smoking and other autoimmune diseases 
has also been found. (Costenbader & Karlson 2006) The possible mechanisms of the 
effect of cigarette smoking on MS risk have been little investigated.  
Treatment 
There is no curative treatment for MS. However, medical treatment strategies for 
relapses in MS, disease-modifying treatment and symptomatic treatment of common 
complaints are the three main areas of intervention. 
Relapses in MS usually have a subacute onset and appears as either new nervous 
system deficits or worsening of previous ones lasting for at least 24 hours. 
(McDonald et al. 2001) Methylprednisolone is recommended to speed up the 
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recovery from the relapse. Intravenous doses of at least 500-1000 mg daily for 5 days 
are recommended, (Sellebjerg et al. 2005) with or without tapering. In some cases, 
oral treatment with dexamethasone 2-4 mg four times daily with tapering is given 
when intravenous treatment can not be accomplished. 
Disease-modifying treatment aims to minimize disease activity in MS to prevent the 
progression of disability, and is indicated only in MS cases with relapsing disease 
activity. (Kappos 2004) Since the early 1990s, four major different disease-modifying 
compounds have become available for MS: interferon-β (IFN-β), glatiramer acetate, 
natalizumab and mitoxantrone. IFN-β is available in recombinant forms for MS 
treatment as IFN-β-1b (Betaferon®, Bayer HealthCare Pharmaceuticals), IFN-β-1a 
(Avonex®, Biogen Idec and Rebif®, Merck Serono). The effects on RRMS of these 
drugs are a reduction in the annual relapse rate by about 30 %, and a reduction of 
disability progression. (Jacobs et al. 1996;PRISMS (Prevention of Relapses and 
Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis 1998;The 
IFNB Multiple Sclerosis Study Group 1995) Similarly as for IFN-β, glatiramer 
acetate (Copaxone®, Teva Pharmaceutical) has been found to reduce the annual 
relapse rate by 30 %. (Johnson et al. 1998) These drugs are recommended as first-line 
treatment in RRMS patients with high disease activity. Initiation of treatment after 
only one clinical episode (but with clinical silent MRI lesions) is found to reduce the 
progression of disability, (Kappos et al. 2007) and is indicated in those at high risk of 
developing clinical definite MS. (Thrower 2007) 
While glatiramer acetate is equally potent in MS as for the IFN-β group of drugs, 
natalizumab (Tysabri®, Biogen Idec and Elan Pharmaceuticals) is found to reduce 
the annual relapse rate by almost 70 % and the rate of disability progression by 42-54 
%. (Polman et al. 2006) Due to the reporting of 2 cases of progressive multifocal 
leucoencephalopathy in MS patients, (Yousry et al. 2006) the drug is recommended 
as second-line treatment. Mitoxantrone may be beneficial after treatment failure of 
the first and second-line treatment. 
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Symptomatic treatment of common afflictions in MS covers a wide range of drugs. 
Common symptoms that are amenable to intervention in MS are bladder dysfunction, 
spasticity, paroxysmal manifestations, neuralgic pain, and depression. Some effects 
can also be found for medical treatment for sexual dysfunction in the male, bowel 
dysfunction and fatigue (Micromedex ® Healthcare Series: 
www.library.ucsf.edu/db/record.html?idrecord=82). 
Pregnancy 
MS typically affects people between 20-40 years, and with a female preponderance of 
2:1. Consequently, the issue of pregnancy is of major concern for many affected 
women. Questions on oral contraceptives, pregnancy, delivery, breast-feeding and 
genetic heritage are frequently asked. (Ferrero et al. 2004) Due to the differences in 
symptoms, disease progression and medical treatment, and social relations, the 
situation for each MS woman will be different. Issues related to pregnancy inevitably 
raise anxiety in MS women and their families.  
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The immune system during pregnancy 
The major role of the immune system is to differentiate between self and non-self. 
Therefore an alteration of the maternal immune system is a prerequisite for a 
successful pregnancy. On the one hand, the fetus must secure its nutrition through 
anchorage of the placenta on the uterine wall, and on the other hand, the initiation of 
an immunologic attack on the fetus must be avoided. Already in the 2nd trimester fetal 
cells are found in maternal circulation. (van, I et al. 2000) The maternal leucocytes 
are essential to balance the immune system towards tolerance to fetal cells. Tolerance 
seems to be antigen-specific since it is induced by the specific presentation of fetal 
antigens via dendritic cells. (von 2008) This antigen presentation uses general 
immunological mechanisms to maintain peripheral tolerance to self-antigens during 
pregnancy. Regulatory T-cells are also important for the development of tolerance, 
and regulatory T-cells can be induced by the dendritic cells. (Steinman & 
Nussenzweig 2002)  
One classical paradigm has been that pregnancy induces a change in the maternal T-
cell activity, with a shift from Th1 (pro-inflammatory cytokine profile) to Th2 (anti-
inflammatory cytokine profile) T-helper cell dominance after conception. (Damek & 
Shuster 1997) Although the Th2 type cytokines appear to contribute to the 
maintenance of pregnancy by controlling the immune and endocrine systems, (Saito 
2000) the picture is more complex. (Chaouat 2007) Regulatory T-cells are found to 
play an important role in autoimmunity as well as in pregnancy. (Wilczynski et al. 
2008) A subpopulation of regulatory T-cells has been found significantly higher in 
pregnant than non-pregnant women. (Sanchez-Ramon et al. 2005)  
Pregnancy is associated with enhanced humoral and reduced cellular immune 
activity, (Wegmann et al. 1993) and a wide array of cytokines balance humoral and 
cellular immunity. The delicate immunological balance in pregnancy is modulated by 
adapted serum levels of corticosteriods, cytokines, hormones (oestrogens, 
progesterons, prostaglandins) and calcitriol, controlled by the fetus, placenta or the 
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mother. Oestriol (pregnancy oestrogen) increases during pregnancy and delivery is 
preceded by a sharp drop in serum levels. Hormones related to pregnancy can directly 
affect the function of both natural killer (NK) cells and macrophages. (Airas et al. 
2007) Finally, there are a broad range of immunoregulatory factors specific for 
pregnancy, including pregnancy-specific serum proteins and tolerance-promoting 
signalling molecules. (Airas et al. 2007)  
Amelioration of MS during pregnancy 
Can some of these immunological changes explain the amelioration seen in MS 
during pregnancy? In MS and other autoimmune diseases, clinical fluctuations during 
hormonal changes related to menstrual cycle, pregnancy and treatment with sex 
hormones have been reported. (Ostensen & Villiger 2007;Voskuhl 2003) Several of 
the immunologically active substances in the serum of pregnant women have known 
anti-inflammatory and immunosuppressant effects in human, and may have clinical 
implications for MS. (Houtchens 2007) In experimental allergic encephalomyelitis 
models, both oestrogen and progesterone are shown to be suppressive. (Trooster et al. 
1993;Trooster et al. 1996) The increased risk of autoimmune disease development 
and flare-up of already established disease in the postpartum period may be a 
consequence of a lack of immune modulation by oestrogen. (Jansson & Holmdahl 
1998) This theory is supported by the positive effects of oral oestriol on MS disease 
activity as measured by repeated MRI. (Sicotte et al. 2002) The mechanisms of 
suppression by the sex hormones are believed to be inhibition of nitric oxide 
production in microglia, decreasing the rate of pro-inflammatory factors synthesised 
by activated microglia. (Drew & Chavis 2000) Pregnancy-associated protein alpha-
fetoprotein and interleukin-10 are also evaluated with regard to the activity of 
immune cells, (Houtchens 2007) and interleukin-10 is known to down-regulate 
cellular immunity. (Saito 2000) 
MS pathogenesis is believed to be dominated by Th1 mediated immune responses. 
(Confavreux et al. 1998;Damek & Shuster 1997) The hypothesis is that Th1 mediated 
immune responses are counteracted by Th2 cell dominance during pregnancy leading 
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to an amelioration of the disease activity. The Th2 cell cytokine predominance has 
been illustrated by cytokine profiles in pregnant women with MS. (Al-Shammri et al. 
2004) A return to Th1 cell dominance postpartum may partly explain the increased 
risk of relapses during the first 3-6 months after delivery. Regulatory T-cells have a 
regulatory effect on the Th1 and Th2 cells, (van den Broek et al. 2005) and are 
believed to create a tolerant microenvironment at the fetal-maternal interface. 
(Zenclussen et al. 2007) Subtypes of this cell are found to prevent auto-reactive T-
cells from inducing autoimmune diseases, (Takahashi & Sakaguchi 2003) but the role 
of regulatory T-cells in relation to pregnancy in MS women is not yet understood. 
Moreover, a subpopulation of NK-cells, found to be increased during late pregnancy 
compared to postpartum in MS patients, (Airas et al. 2007) may limit the survival of 
activated T-cells. (Bielekova et al. 2006) Which of these immunological changes 
during pregnancy is most important for the disease amelioration during pregnancy is 
yet to be determined. Still, knowledge in this field will illuminate aspects of the 
pathogenesis of MS that may suggest new treatment strategies. 
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MS and reproductive health 
Prior to 1970, many studies on the effects of pregnancy on MS showed conflicting 
results, probably due to methodological weaknesses such as selection and recall bias. 
(Damek & Shuster 1997) As a result, in earlier periods MS women were to some 
degree advised against pregnancy and sometimes even recommended abortion, due to 
the fear that pregnancy could worsen the course of the disease. With the 
establishment of diagnostic criteria by Schumacher and co-workers in 1965, larger 
and methodologically sounder studies led to the consensus that MS relapse rate was 
not increased during the 9 months of pregnancy. (Korn-Lubetzki et al. 1984;Nelson et 
al. 1988) Several studies during the last decades have reported reduction in relapse 
rates during pregnancy (Confavreux et al. 1998;Roullet et al. 1993;Sadovnick et al. 
1994) and no negative effects of pregnancies on the long term prognosis of MS. 
(Poser & Poser 1983;Roullet et al. 1993) This has contributed to a shift towards a 
positive attitude concerning birth-giving in MS women among health professionals 
and the patients themselves. Availability of disease-modifying therapies and the 
relatively low risk of transferring MS to offspring (Ebers et al. 1995) should also be 
reassuring for women who plan to become pregnant. 
With the increasing number of pregnancies and births to MS women, there is an 
increasing need for information on these issues among the women and their families.  
Obstetricians, midwives and anaesthetists ask for information regarding medication, 
delivery interventions, caesarean section and anaesthetics in pregnant MS women. 
(Ferrero et al. 2004;Ferrero et al. 2006)  
 
Pregnancy and its effect on MS 
Short term effects 
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Both retrospective (Salemi et al. 2004) and prospective (Confavreux et al. 1998) 
studies have illustrated a significant decrease in numbers of relapses in the third 
trimester of pregnancy with a succeeding increase in the first months after delivery. 
The Pregnancy in Multiple Sclerosis (PRIMS) study, (Confavreux et al. 1998) was a 
large prospective, multicenter study, where 269 pregnancies among 254 MS women 
were followed up until 24 months after delivery. The study illustrated a maximal 
reduction of the relapse rate with 70 % in the third trimester followed by a 70 % 
increase in the first three months postpartum, as compared to the pre-pregnancy 
relapse rate. In sum, the relapse rate during the pregnancy plus the first 3 months 
postpartum was equal to the pre-pregnancy relapse rate. These findings were partially 
confirmed by two smaller prospective studies. (Sadovnick et al. 1994;Worthington et 
al. 1994) It has also been shown that the relapses tend to be milder during pregnancy, 
(Roullet et al. 1993) and more severe in the postpartum period. (Worthington et al. 
1994) The changes in disease activity during pregnancy have additionally been 
illustrated on repeated MRI examinations by reduction in the number of active 
lesions during the second half of pregnancy followed by an increase during the first 
months postpartum. (Paavilainen et al. 2007;van Walderveen et al. 1994) 
Unfortunately, studies on the effect of pregnancy on disease progression in women 
with primary progressive MS are lacking. Also due to lack of studies there is 
uncertainty whether permanent symptoms like fatigue, bowel and bladder 
disturbances and ambulatory problems of MS women can be aggravated during 
pregnancy. However, pregnancy and childbirth have been found not to influence the 
characteristics of urinary disorders in MS women. (Durufle et al. 2006) 
In the high-risk period of relapses the first 3 months postpartum, 28 % of the MS 
women in the PRIMS study experienced a relapse. (Confavreux et al. 1998) The 
clinical factors found to predict a postpartum relapse were relapse experienced during 
the pre-pregnancy year and during pregnancy. (Vukusic et al. 2004) In a smaller 
study, the women’s past history of relapses was found as the best indicator for the 
clinical course of MS in pregnancy and after delivery. (Sadovnick et al. 1994) Breast-
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feeding did not influence the risk of postpartum relapses. (Achiron et al. 2004;Nelson 
et al. 1988)  
Long term effects 
It has been debated whether pregnancy affects MS disease progression in the long 
run. (Bennett 2005) Pregnancy and childbirth did not influence disability in a 
prospective study of 32 pregnancies in a population of 125 MS women, (Roullet et al. 
1993) and in another smaller prospective study where the MS women were followed 
up for 3 years postpartum. (Worthington et al. 1994) Similarly, no acceleration in the 
development of disability postpartum was found in the PRIMS study. (Confavreux et 
al. 1998;Vukusic et al. 2004) In a retrospective population-based Canadian survey of 
term pregnancies in a population of 185 MS women, no association between long-
term disability and worsening of the disease during pregnancy and the postpartum 
was detected. (Weinshenker et al. 1989b) The timing of birth relative to onset of MS 
has been shown not to affect the long-term disability. (Thompson et al. 
1986;Weinshenker et al. 1989b) This was contradicted in another study that reported 
a decreased risk for a progressive course in women who were pregnant after MS 
onset compared to before. (Runmarker & Andersen 1995) But the authors 
commented that the results could have been influenced by selection bias, since MS 
patients with a high disease activity and frequent relapses might have tended to avoid 
pregnancies.    
Postpartum follow-up 
Postpartum MS relapse can prevent maternal care-giving, due to hospitalization and 
separation, and can lead to unsatisfactory mother-child bonding. In a German study, 
(Poser & Poser 1983) it was found that up to 30 % of the MS mothers were prevented 
from giving their newborn adequate care due to their MS. A population-based cohort 
study showed that women with MS twice as often as control women were 
hospitalized within the first three months after delivery.(Mueller et al. 2002)  
 25
Fatigue can be very pronounced in MS, and increase the need for help in the family. 
Domestic help, supplementary feeding instead of mother’s milk, separate bedrooms 
mother-child should be assessed individually. A major challenge in a family in which 
the mother has MS is to raise the question of the family’s needs, and to secure that 
relief efforts can be introduced early when necessary. More studies are needed to 
better identify those MS women with a high risk for postpartum relapses.  
MS effect on pregnancy, delivery and birth outcome 
There are few large-scale studies on the effect of MS on pregnancy, delivery and 
birth outcome. Prospective data from the PRIMS study showed no effect of MS on 
the risk of miscarriage, stillbirth and congenital malformations. (Confavreux et al. 
1998) This has been supported in other studies on pregnant MS populations. (Achiron 
et al. 2004;Sadovnick et al. 1994) A population-based cohort study of 198 MS 
women reported that maternal anaemia was increased compared to non-MS controls, 
but there was no increase in pregnancy or delivery complications. (Mueller et al. 
2002) Nor was any increase in low birth weight (LBW), preterm births or 
malformations detected. A prospective study of 15 pregnant MS women reported few 
pregnancy and birth complications, and normal distribution of birth weight and head 
circumference in newborns. (Worthington et al. 1994)  
MS and anaesthetics and operative intervention 
Reliable data on the relapse risk in MS women having anaesthesia and operative 
interventions during birth is scarce. Epidural anaesthesia during labor is considered 
safe for women with MS, (Achiron et al. 2004;Confavreux et al. 1998) and is 
preferred to spinal anaesthesia due to presumed neurotoxic effects to demyelinised 
spinal neurons with a potential postoperative worsening of the disease. This 
preference is not supported by robust studies. However, a study of 32 pregnancies 
indicated increased risk of relapses in MS women who received higher concentrations 
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of local anaesthetic agents. (Bader et al. 1988) A high concentration of local 
anaesthetic in the CSF has been found also in the spinal cord after spinal technique 
was used in dogs. (Cohen 1968) Epidural anaesthesia did not influence the risk of 
postpartum relapse in the MS mother. (Vukusic et al. 2004) But a recent 
questionnaire study among UK obstetric anaesthetists revealed a lower threshold for 
administering a general anaesthesia to MS women than to healthy women. (Drake et 
al. 2006) However, the majority preferred regional anaesthesia for labor and 
caesarean section. 
The criteria for operative intervention during birth in MS mothers are in principle 
exactly the same as for healthy non-MS women. MS-related motor symptoms such as 
spasms, decreased muscle tone or control in lower abdomen and extremities may 
however affect the birth process. Fatigue can increase exhaustion and make the use of 
forceps necessary. (Davis & Maslow 1992) Vacuum extraction during delivery has 
been reported increased among MS women. (Mueller et al. 2002) Mental symptoms 
related to MS, such as fatigue, can influence the decision regarding caesarean section 
and other operative interventions during birth. Surgical procedures in general have 
been reported not to affect the relapse rate in MS women. (Sibley et al. 1991) The 
rate of complications after a caesarean section is found to be 21.4 % in a Norwegian 
cohort of 2751 caesarean sections representing the general population, and the 
complication rate was higher for patients who received general anaesthesia compared 
with regional anaesthesia, and the risk of complications increased the further labor 
had progressed. (Hager et al. 2004) Antibiotics are recommended for all patients with 
emergency caesarean delivery in Norway, which is supported by a Cochrane review. 
(Smaill & Hofmeyr 2002)  
MS, smoking and pregnancy 
Although a limited response rate (50 %), smoking frequency among MS patients has 
not been found increased compared to reference populations. (Friend et al. 
2006;Turner et al. 2007) The smoking rate was high (40 %) in a Norwegian MS 
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population, (Nortvedt et al. 2005) but the smoking rate has not been examined in the 
birth-giving part of the MS population. Possible effect of passive smoking was 
recently shown in a study of 129 cases of childhood MS reporting that their parents 
were more frequently smokers compared to a large group of matched controls. 
(Mikaeloff et al. 2007) Among those with RRMS the risk of developing SPMS is 
higher in smokers than in non-smokers. (Hernan et al. 2005)  
The smoking rate in pregnancy has been decreasing during the last decades in the 
Nordic countries, (Ericson et al. 1991;Eriksson et al. 1996) and the smoking rate at 
the end of pregnancy was as low as 10.4 % in Norway during 2004 
(www.fhi.no/eway/default.aspx?). Birth weight is reduced by a mean of 200g if the 
mother smokes during pregnancy. (Haug et al. 2000) The correlation between 
smoking and birth weight exists irrespective of other causes for reduced birth weight, 
(Haug et al. 2000;Kramer et al. 1990) and a dose-response relationship has been 
found. (Kallen 2001) Smoking during pregnancy increases the rate of being small for 
gestational age (SGA) infants, preterm birth and perinatal death. (Kallen 
2001;Raatikainen et al. 2007) Stopping smoking during pregnancy reduces the 
reduction of birth weight, since the effect of smoking on birth weight is strong close 
to term. (Ananth & Platt 2004) In addition, smoking can represent an extra hazard to 
pregnant MS women. 
MS and medication during pregnancy 
Conception often occurs unplanned while women are receiving disease-modifying 
therapy or symptomatic medication. IFNβ taken by MS patients has generally been 
recommended discontinued before conceiving, or at least when pregnancy is 
suspected or confirmed. The large size of the IFN molecules may inhibit transferral 
across the placental barrier, as suggested from analysis of women treated with IFNα. 
(Pons et al. 1995) Limited data on pregnancy outcomes in women exposed to IFNβ 
have shown a slightly increased rate of miscarriages (Sandberg-Wollheim et al. 2005) 
and a slight reduction in birth weight. (Boskovic et al. 2005) A recent retrospective 
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study of 34 pregnant MS women exposed to disease-modifying therapy during 
pregnancy showed no effect on pregnancy outcomes. (De, V et al. 2007) The 
numbers of women exposed to IFNβ during conception or later in pregnancy are too 
small to provide reliable data, and discontinuation of IFNβ is still recommended. 
Since there is no evidence of teratogenicity or birth defects related to IFNβ therapy, 
induced abortion is not indicated. IFNβ can in exceptional cases be continued in 
pregnancy after a clinical consideration has shown that treatment is essential for that 
woman.  
Glatiramer acetate used in pregnancy has not been shown to increase the risk of fetal 
malformations. However, some adverse drug reactions related to pregnancy have 
been reported, like spontaneous abortions. (Tremlett & Oger 2008) Since there are no 
reliable data so far, this drug is not recommended in pregnancy. Pregnant women on 
this drug should continue using it only if regarded as absolutely essential. 
Natalizumab has not been studied in pregnant women, and is contraindicated during 
pregnancy. Mitoxantrone is not recommended during pregnancy due to its strong 
immunosuppressant activity, teratogenicity in rats and the lack of data on security. 
Methotrexate and cyclophosphamide are not recommended used during pregnancy 
due to teratogenicity. Intravenous immunoglobulin (IVIG) can be used safely during 
pregnancy. (Achiron et al. 2004) 
Prednisone is not recommended in the first trimester due to the increased risk of oral 
cleft. (Park-Wyllie et al. 2000) Acute relapses in MS women during pregnancy can be 
treated with methylprednisolone and prednisone in the second and third trimesters, 
and short-term high-dose regimes on methylprednisolone is preferable in the same 
manner as for non-pregnant women. (Sellebjerg et al. 2005) Due to adverse effects of 
glucocorticoids, like gestational diabetes, hypertension, oedema and premature 
rupture of membranes, tapered courses should be avoided during pregnancy. (Ferrero 
et al. 2006)  
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Fatigue, bladder and bowel dysfunction, spasticity, movement problems and pain can 
be aggravated during pregnancy. The majority of medications indicated for these 
problems are contraindicated during pregnancy, (Schwendimann & Alekseeva 2007) 
according to the U.S. Food and Drug Administration (www.fda.gov/). MS women 
have a higher risk for urinary tract infections during pregnancy. Chronic infections in 
MS patients can be treated with drugs like nitrofurantoin or ampicillin.  
MS, breast-feeding and medication 
Breast-feeding rates in Norway have increased from a bottom level in the late 1960s, 
when 30 % breastfed for 3 months or more, (Liestol et al. 1988) to 1991, when more 
than 95 % were breast-feeding their baby when discharged from the maternity clinic. 
(Heiberg & Helsing 1995) Breast-feeding does not influence postpartum relapse 
frequency or severity. (Confavreux et al. 1998;Vukusic et al. 2004) Thus, breast-
feeding can be encouraged in MS women. A recent multicentre study on IVIG post 
partum in 163 MS women revealed that 85 % breastfed, and two thirds of them for 3 
months or more. (Haas & Hommes 2007) The MS mother’s ability to nurse or care 
for the baby can depend on the disease activity postpartum and the level of disability. 
Stress related to the maternal sleep deprivation during the postpartum period can be 
alleviated by somebody else feeding the baby with pumped breast milk at night time.  
If the MS mother needs medication in the postpartum nursing period, there will be 
concern about whether the drugs or metabolites pass into the breast milk. According 
to Norwegian guidelines (www.relis.no), medium dose methylprednisolone can be 
given when medication is required for postpartum relapses, due to low transmission 
across placenta in doses 80mg or less per day and a half life of maximum 4 hours. 
(Hale 2006) With higher doses, corticosteroids will secrete into the breast milk and 
can cause growth suppression and reduced bone density in the baby due to 
interference with endogenous corticosteroid production. IFNα is not excreted in 
human breast milk at clinically relevant levels, (Kumar et al. 2000) but it is not 
known to what extent IFNβ is absorbed in the baby, and IFNβ therapy is therefore not 
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recommended during breast-feeding. It is not clarified whether glatiramer acetate 
passes into the breast milk. A survey study of women neurologists’ practice 
illustrated that nearly 86 % did not prescribe disease-modifying medication to MS 
patients during breast-feeding, and if it was used, glatiramer acetate was the most 
frequent drug. (Coyle et al. 2004) Mitoxantrone and cyclophosphamide are found in 
breast milk and should not be used during breast-feeding. If a disease-modifying drug 
is indicated, and the mother has a strong wish to continue breast-feeding, IVIG 
therapy is reported to reduce the attack rate without adverse effects on the baby, 
(Achiron et al. 2004;Haas & Hommes 2007) and is thus regarded as safe during 
breast-feeding.  
General trends in obstetric care 
Important developments in obstetric care in Norway since the foundation of the 
Medical Birth Registry of Norway (MBRN) in 1967 have been the progress in 
obstetric techniques and routines for antenatal, intra-partum and postnatal care. 
Especially the enhanced in utero monitoring has resulted in more premature children 
being rescued. Increased operative intervention and especially more planned 
caesarean sections represent a major change during these years.   
There has been a world-wide increase in the rate of caesarean section during the last 
decades. (Black et al. 2005;Menacker et al. 2006) In Norway, this rate has increased 
gradually from 2 % in 1967, to 13.6 % in 1998 and 16.3 % in 2006 
(www.fhi.no/eway/default.aspx?). Several explanations have been suggested for this 
increase, such as technological tools enhancing early intrauterine diagnosis, 
preference for caesarean section with term breech presentation, (Hannah et al. 2000), 
increase in maternal age, increased proportion of nullipara and plural births, as well 
as previous caesarean section. A Norwegian prospective survey for the years 1998-9 
illustrated that emergency caesarean sections account for 64.3 % of all caesarean 
sections. (Kolas et al. 2003) The repeat caesarean section rate was as high as 50 % in 
this study, and the most frequent indications for planned caesarean section were 
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previous caesarean section and maternal request. In comparison, the repeat caesarean 
section rate was almost 90 % in the US in 2004. (Menacker et al. 2006)  
The attitude among women towards their right to choose delivery mode has been 
changing. (Bettes et al. 2007) However, the range of personal reasons for requesting 
caesarean section varies between countries and social classes. (McCourt et al. 2007) 
The increase in caesarean section rate has been found not to lower perinatal mortality. 
(Eckerlund & Gerdtham 1999) Compared with planned vaginal birth, planned 
caesarean delivery increased the transfer rate to the neonatal intensive care unit from 
5.2 % to 9.8 %. (Kolas et al. 2006) 
More premature children are rescued due to improved antenatal care, prenatal 
diagnostic tools and premature intensive care units. Increased maternal age, plural 
births and the rate of extremely premature children can alter the frequencies of 
neonatal conditions and further the morbidity. The quality of the obstetric care can be 
measured as the rate of perinatal mortality. The rate of perinatal mortality (among 
foetuses ≥500g which corresponds to the birth weight at 22 weeks of gestation) in 
Norway has decreased from 2.2 % in 1967, to 1.2 % in 1980 and 0.4 % in 2005 
(www.fhi.no/eway/default.aspx?). Recent numbers show similar perinatal mortality 
rates in all Scandinavian countries (Health statistics in the Nordic countries 2005. 
Copenhagen: NOMESCO 80:2005).  
Small obstetric units are located in scarcely populated regions of Norway. However, 
during the last 20 years obstetric care in Norway has been centralized, (Nilsen et al. 
2001) and this has also been reported in Finland. (Viisainen et al. 1999) The very 
small units (<100 births per year) have doubled neonatal morbidity compared to the 
units with 2001-3000 births per year, also after accounting for differences in selection 
to small and large units. (Moster et al. 1999) The experience, expertise, and 
equipment of larger institutions can reduce the risk of neonatal death to a minimum 
both for low-risk and high-risk deliveries.  
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Aims of the study  
The objective of this thesis was to explore whether birth-giving is affected by 
multiple sclerosis, by four papers analysing the following:  
 
I. The effect of maternal MS upon pregnancy, delivery and the newborn, 
including MBRN data during 1967-2002 (Paper I).  
II. The effect of maternal MS upon pregnancy, delivery and the newborn: an 
analysis of planned vaginal deliveries, including MBRN data during 1988-
2002 (Paper II). 
III. The effect of maternal MS upon pregnancy, delivery and birth outcome by 
comparing births before onset of MS, births between onset and diagnosis 
of MS and births after MS diagnosis. A coupled data file from the MS 
Registry and the MBRN during 1967-2002 was included (Paper III). 
IV. The effect of smoking as a possible risk factor for the lower birth weight of 
the neonates in MS births. Smoking habits and social factors in pregnant 
MS women versus references were analysed for MBRN data during 1998-
2005 (Paper IV).  
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Materials and Methods  
The studies in this thesis are population-based historical cohort studies, utilizing the 
data of two registries: the Medical Birth Registry of Norway and the Norwegian MS 
Registry. 
The Medical Birth Registry of Norway  
The Medical Birth Registry of Norway (MBRN) was established in 1967 by the 
Directorate for Health and Social Affairs. It is a complete, nationwide registry based 
on the compulsory notification of all births after 16 weeks of gestation (12 weeks 
from December 1, 1998). It is one of seven health registries in Norway. From 2002 
the registry has been run by the Norwegian Institute of Public Health. A standardized 
notification form (Appendix 1) was principally unchanged from 1967 to 1998. A new 
and revised notification form has been used since December 1, 1998 (Appendix 2). 
The form is filled in by the physician and midwife assisting during the delivery and 
based on information from: 
1) A standard form used during pregnancy by the woman’s physician 
2) Information given by the woman when admitted to hospital 
3) Information from the physician and midwife about the actual delivery and the 
newborn. 
The registry contains comprehensive data on demographics, maternal health, and 
previous reproductive history, complications during pregnancy and delivery and 
pregnancy outcome. The newborns are examined medically by a physician, usually a 
paediatrician, before discharge from the hospital, and all neonatal diagnoses recorded 
are based on these examinations. The attending midwife is responsible for 
completion of the notification form and the attending physician is a co-signer. 
Complete ascertainment of the MBRN is accomplished through record linkage to 
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Statistics Norway. Linkage to other patient or health registries is possible since every 
inhabitant of Norway has a unique personal identification number, allocated shortly 
after birth. Using the mother’s identification number, linkage to the National 
Population Registry, run by Statistics Norway, can yield the identification number of 
the newborn.  
The MBRN is a valuable resource for information on the effect of maternal disease 
on pregnancy, delivery and birth outcome. Data have been collected and evaluated 
for other patient groups. Births by women with myasthenia gravis, (Hoff et al. 2003) 
connective tissue disease and inflammatory rheumatic disease, (Skomsvoll et al. 
2000) and polio, (Veiby et al. 2007) have been investigated with an epidemiological 
approach due to the advantageous nationwide MBRN. 
Linkage of data from the MBRN and from other registries requires approval from the 
Regional Committee for Medical Research Ethics, the Data Inspectorate, and the 
Directorate of Health and Social Affairs.  
The Norwegian MS Registry  
The Norwegian MS Registry was established in 1998 and financed through a grant 
from the Social and Health Department. The Norwegian Multiple Sclerosis 
Competence Centre, Department of Neurology, Haukeland University Hospital runs 
and harbours the MS Registry, which registers demographic, clinical and treatment 
variables on (preferably all) MS patients in Norway (Appendix 3). The year of onset 
and diagnosis of MS is recorded. The MS onset is defined as the year when the first 
MS related symptom occurred, with the neurologist interpreting the patient history. 
The MS diagnosis is set according to McDonald criteria. (McDonald et al. 
2001;Polman et al. 2005a) The validation of the reported year of onset and year of 
diagnosis has not been done systematically in the MS Registry. The patient history, 
symptoms and clinical signs, and the results of the paraclinical investigations may be 
evaluated in each case.  
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The registration is based on written informed consent, given to the local neurologist. 
(Myhr et al. 2006) The first patient was registered in 2001, and the registry included 
3087 patients per May 2005. Given a prevalence of MS of 150 per 100,000, (Grytten 
et al. 2006), this accounted for almost 50 % of all MS patients in Norway. Linkage to 
the National Population Registry enabled us to exclude those patients that were dead 
(64 patients). The 3023 MS patients alive who were the source population for Paper 
III, had a relapsing remitting MS rate of 86.7 %, mean age at onset of 33.1 years and 
included 67 % women, indicating that this was a representative MS population. 
(Celius & Vandvik 2001;Dahl et al. 2004;Grytten et al. 2006) Written informed 
consent from the patients was necessary to link the MS Registry to the MBRN. 
Information was sent to all 3023 patients, followed by a reminder to those patients 
(901) that had not responded to our approach. The collection was then closed, and 
2560 patients, 1755 women, had consented to record linkage. A total of 463 patients 
had for various reasons not answered or not answered yes (6 had wrong addresses, 1 
claimed wrong diagnosis, 11 refused and the rest had recently died or did not answer 
for other reasons). The proportion of women was 68.6 % in the consenting versus 
59.7 % in the non-consenting group.  
Of the 1755 consenting women, 1371 were registered with a total of 2783 births in 
the MBRN. Linkage of the MBRN and the MS Registry gave unique access to a large 
material of women with MS that had gone through pregnancy and birth at different 
stages of their disease.  
MS and reference groups 
In Paper I all births registered in MBRN from January 1, 1967 to December 31, 2002 
were included. Among these 2,103,079 births, a diagnosis of MS coded as 340 
(International Classification of Diseases (ICD)-8) or G35 (ICD-10) was noted in 461 
mothers with 590 births. In 45 (9.8 %) of the MS mothers, the MS diagnosis was 
missing on one or more of the consecutive births (n=59). Since MS is a chronic 
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disorder with persistent immune mediated lesions in the central nervous system, we 
included these births in the MS group. These 59 births did not differ from the 590 MS 
coded births regarding complications during delivery, rate of operative delivery and 
neonate’s characteristics. Thus, the study population consisted of 649 births. The 
reference group consisted of all remaining 2,102,430 births. Plural births were not 
excluded from any analyses other than the calculation of SGA. 
In Paper II, we wanted to evaluate the delivery and birth outcome among women who 
were planned to have a vaginal delivery, which were women who underwent a 
vaginal delivery or an emergency caesarean delivery. From 1988, caesarean delivery 
was classified as planned or not, and we therefore included MBRN births during 
January 1, 1988 to December 31, 2002. A total of 449 MS births were compared to 
815,060 reference births. 
 
In Paper III the database was generated by the linkage of MBRN (January 1, 1967 to 
December 31, 2002) and the MS Registry. The births were categorized to pre MS, 
that was birth prior to year of MS onset; early MS, that was birth between the year of 
onset (included) and the year of diagnosis; and manifest MS, that was birth from the 
year of diagnosis (included) and later. If only the year of either onset or diagnosis 
was known (n=54), the birth was placed in the group with the assumed highest risk 
(later MS stage), to yield bias towards zero. If neither the year of onset nor the year of 
diagnosis was recorded exactly in the MS Registry, all births from that woman were 
excluded from the study (n=10). This led to a total of 1910 pre MS births, 555 early 
MS births and 308 manifest MS births in 1368 women. The mean age of MS onset 
for all included MS mothers was 33.3 years. Only the MS diagnosis from the MS 
Registry was used in Paper III, in contrast to the other Papers which used the MS 
diagnosis noted in the MBRN. The non-MS reference births in Paper III included all 
births during the same time period with no MS registered in the MS Registry and 
consisted of 2,100,281 births. The non-MS reference births included 441 births where 
MS was recorded in the MBRN (but not in the MS Registry). Since this accounted for 
only 0.02 % of the total, they were not excluded from the non-MS references. For 
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some birth weight analyses the groups early and manifest MS were grouped together 
(n=863) as births after onset of MS, and compared to pre MS births (n=1910).  
The majority of the MS women (86.4 %) had births in only one of the three 
categories, and only 0.4 % of the mothers had births in all three categories. Of all 
births one year or more after the MS diagnosis, 74.7 % was recorded in MBRN with 
a diagnosis of maternal MS, and the accordance increased the longer since the MS 
diagnosis. 
In Paper IV, data on smoking from December 1998 to October 2005 was collected. 
Such information has been registered in the MBRN from December 1, 1998. Linkage 
to Statistics Norway generated information on the mother’s highest attained 
educational level by December 2004, as well as employment status. A total of 
372,128 births were registered, and in 250 of them the mother was registered with 
MS. All the non-MS births were included in the reference group. Since this database 
did not contain maternal serial numbers, we could not link births by the same mother.  
 
Information on smoking, included in the standard birth registration form used from 
December 1, 1998, was given by the birth-giving mother on her admittance to 
hospital. Smoking was registered as no smoking or daily smoking, recorded both for 
the beginning and for the end of the pregnancy. Those who reported smoking only 
occasionally at the end of the pregnancy (1.4 %) were grouped as non-smokers. Since 
97 % of those who reported daily smoking at the end of the pregnancy also reported 
daily smoking at the beginning, we defined this group as smokers during the entire 
pregnancy. Twenty-seven births in the MS group were reported as daily smokers at 
the end of the pregnancy. They constituted the target group in the analyses on adverse 
birth outcome to evaluate if smoking was an extra hazard for women with MS. 
Smokers at the beginning of the pregnancy but not at the end (n=15) were classified 
as non-smokers for the analyses of birth outcome.  
For the analysis of smoking rate, the cases that lacked information on smoking both 
at the beginning and at the end of the pregnancy were excluded. The frequency of 
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totally missing smoking information was equal in the MS and the reference groups 
(14.0 %) and amounted to 35 births in the MS group and 52,203 in the reference 
group.  
Variables and classification 
The variables in Paper I-IV were generally based on the variables which exist in the 
MBRN. The variables have been defined after consensus in a group consisting of 
obstetricians, epidemiologists and neonatologists. The following variables were 
studied: 
Descriptive variables: 
- Year of birth 
- Age of mother (completed years) 
- Marital status 
- Maternal diseases before or during pregnancy (MS, inflammatory arthritis, 
urinary tract infections, hypertension, haemorrhage, anaemia, diabetes 
mellitus, rubella, epilepsy, thyroid condition) 
- Type of obstetric institution (university hospital or not) 
- Birth order (parity), mean parity of all births 
Outcome variables: 
- Birth weight (g), length (cm) and head circumference (cm) 
- Sex of the neonate 
- Gestational age in days and completed weeks 
- Preterm birth (less than 37 weeks of gestation) 
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-  Pregnancy complications (any complication and preeclampsia defined as 
increased blood pressure after 20 weeks of gestation with proteinuria, oedema 
or both) 
-  Complications during delivery included slow progression of the second stage 
of labor (defined as a duration of more than 60 minutes, or more than 75 
minutes with epidural anaesthetics) (Bergsjoe et al. 1993), postpartum 
haemorrhage and presentation anomalies.  
-  Induction of delivery (perforation of amniotic membranes and/or infusion with 
oxytocin and prostaglandin) any time during delivery  
-  Operative interventions (use of a vacuum extractor, forceps or caesarean 
section) 
-  Outcome variables regarding the neonate were Apgar scores (at 1 and 5 
minutes), stillbirth, perinatal mortality (all fetal deaths after 16 weeks (12 
weeks since 1998) of pregnancy and deaths up to 7 days after birth) and birth 
defects (further classified as severe or not, based on ICD-8 until December 
1998 and thereafter ICD-10).  
-  Small for gestational age (SGA) was defined as birth weight below the tenth 
percentile at the attained gestational age. We used a standard for birth weight 
by gestational age based on MBRN data, which exclude stillbirths, plural 
births, neonates with birth defects and births by caesarean section. (Skjaerven 
et al. 2000) The standard was applied on all singleton births with attained 
gestational age 28 to 44 weeks and term births (37 or more weeks).  
- High birth weight was defined as 4500 grams or more independent of 
gestational age. Low birth weight (LBW) was defined as below 2500 grams 
(in births ≥28 weeks of gestation).  
From 1988, caesarean section was classified as planned or not. From 1999, mother’s 
medication during pregnancy as well as smoking habits was registered.  
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Additional variables after linkage of MBRN and the MS Registry (Paper III)  
- Year of MS onset 
- Year of MS diagnosis 
- Initial course of MS (RRMS or PPMS) 
- Duration of MS from onset to time of giving birth, and from MS diagnosis to 
time of giving birth (in years) 
 
Additional variables in the database with information on smoking (Paper IV) 
- Smoking: no smoking and daily smoking, at the beginning and at the end of 
the pregnancy. Only daily smokers at the end of pregnancy were grouped as 
smokers, and 97 % in this group also smoked daily at the beginning of the 
pregnancy.  
- Ever smoking (those who smoked to some degree at the beginning or at the 
end of pregnancy) 
- Maternal cohabiting status 
- Highest attained education in years (high educational level with education for 
13 years or more, or low level with less than 13 years)  
- Employment status (full-time, part-time or not working)  
- Miscarriages (less than 24 weeks gestation) in earlier pregnancies  
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Statistics 
For statistical analysis we used the Statistical Package for the Social Sciences (SPSS, 
Chicago IL) for Windows version 13.0 and 14.0. Pearson chi-square tests were used 
to compare categorical variables. Fisher’s exact test was used for tables with expected 
cell frequency lower than 5. Arithmetic means were calculated for neonatal 
anthropometrics and gestational age. Means of continuous variables for two groups 
were compared by Student’s t-test. Means of continuous variables for the three 
groups in Paper IV were compared in a one-way ANOVA test. The power to detect a 
given difference in mean birth weight between two groups was estimated in the 
adjusted linear regression model (Papers III and IV). The power to detect a given 
difference between the MS and reference smokers in the categorical variables listed 
in Table 2, Paper III was calculated in S-Plus (Insightful, Seattle). All tests were two-
sided, and a statistical significance level of 0.05 was used. 
Stratification, effect modification and confounding 
Confounding represents a confusion of effects, where an apparent effect of the 
exposure is distorted by a confounder. A confounder must be associated with the 
exposure, it must be a risk factor for the outcome, and it must not be an intermediate 
step in the causal pathway between the exposure and the outcome. A confounder can 
be attempted managed during analysis. Possible effect modifiers or confounders such 
as time period, mother’s parity, mother’s age, and educational level, were considered 
by stratification and secondly by linear regression or unconditional logistic regression 
analysis. In some analyses (Paper III) gestational age and caesarean section were also 
evaluated as confounders. Statistical testing of effect modification was evaluated by 
including an interaction term in the logistic regression model (Paper IV).  
To detect possible changes over time due to trends in obstetric care, management of 
MS patients and MS diagnostic criteria, the material was subdivided into three time 
periods: 1967 to 1980; 1981 to 1990 and 1991 to 2002. Data of operative intervention 
were presented in strata according to these periods in Paper I. For the association MS 
and operative intervention in Paper III, time period was divided into 6 categories, 
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since time period was a very strong confounder for the association between MS and 
operative interventions. This was due to the skewed representation of births at the 
different stages of MS in the different time periods, illustrated in table 1 in Paper III. 
Due to the higher ascertainment of cases with a recent diagnosis of MS in the MS 
Registry (see Methodological considerations), as well as an increasing number of 
births to MS women throughout the period, the group of manifest MS births was 
overrepresented in the last time period compared to pre MS births (Paper III). The 
increasing number of MS births throughout the examined time period was a major 
finding also in Papers I and II. As a consequence, time period was a strong 
confounder for nearly all our studied variables and especially for caesarean section 
due to the changing attitudes to caesarean section among pregnant women and 
obstetricians during these years. (Black et al. 2005) There were also effects of time 
period on birth weight, possibly due to changes in mothers’ lifestyle. (Skjaerven et al. 
2000)  
Births were stratified by parity (first, second and third or more). Mean parity was 
similar in the MS and the reference group (Papers I and II). However, in the analysis 
of birth weight and smoking in Paper IV, it was necessary to adjust for parity. 
Maternal age is a confounder for many birth outcomes. This variable was stratified in 
completed years at birth-giving (less than 25, 25 to 29, 30 to 34 and 35 years or 
more). Since the MS group as expected had a higher mean age at the time of giving 
birth, and high maternal age in itself can account for differences in the neonates’ 
anthropometrics, maternal age was typically included as a categorical covariate in the 
multivariate models.  
The highest attained educational level for the mother was only available in the 
database used for Paper IV. Educational level was a strong confounder for the 
association between smoking in pregnancy and MS. This association was further 
complicated by the declining smoking rates during the period 1998-2005. Data on the 
highest attained educational level was imported from Statistics Norway by January 
2005, and our database contained births from the period December 1998 to October 
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2005. We could expect an effect of the difference in mean maternal age between the 
MS and the reference group for comparison of educational level. The groups were 
made comparable for educational level by excluding births by mothers <25 years of 
age.  
Age of gestation was stratified as less than 37 weeks (preterm births), 37 to 42 weeks 
(term births) and 43 weeks or more. In Paper III, the effect of MS on birth weight was 
adjusted for gestational age. This was done in order to evaluate whether the decrease 
in mean birth weight in term births observed among MS mothers could be due to the 
increased use of obstetric intervention in the MS group, such as use of caesarean 
section. An alternative to adjustment for gestational age might have been to adjust 
directly for caesarean delivery. However, since conditions leading to LBW can by 
themselves cause caesarean section, we found it not justified to include caesarean 
section as a confounder for the association MS and birth weight. Reduced birth 
weight in the manifest MS group compared to the pre MS group remained also after 
inclusion of gestational age (in weeks) in the multivariable model. In Paper II, the 
planned caesarean sections were excluded for all analyses. In these analyses, no 
difference in gestational age was observed between the MS group and the references. 
Since the indications for planned caesarean section can be different in MS and non-
MS births due to the patients’ and health professionals’ attitudes, such an exclusion 
of planned caesarean section can imply selection bias. This is commented on in 
Methodological considerations. 
 
Low age of MS onset could be associated with a more advanced disease at the time of 
pregnancy and delivery. Therefore, age of MS onset was considered as a possible 
confounder (Paper III). Our study design included grouping of births in three 
different stages of MS. The pre MS group (giving birth before any MS symptom) 
would naturally have a significantly higher mean age of MS onset compared with the 
other two groups, giving birth after MS debut (early MS, manifest MS) illustrated in 
Table 1, Paper III. However, since adjustment for age of onset did not change the 
association between manifest MS and birth weight, we did not include age of MS 
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onset in our final analysis. In a larger dataset of MS cases, one could have included a 
stepwise duration of the disease from MS onset to the year of birth to see if there is a 
trend for duration of MS regarding negative birth outcome in this patient group.  
Medication during pregnancy was not registered in MBRN until 1999, but would 
have been interesting to evaluate as a possible confounder. However, since MS 
specific disease-modifying therapy including cortisone-like drugs were not reported 
used in pregnancy during the period 1999-2005 in the MS group (all Papers), we can 
discount any effect of such treatment for our studied associations.  
Ethical approval 
The study was approved by the Regional Committee for Medical Research Ethics 
Review in West-Norway, the Directorate of Health and Social Affairs in Norway as 
well as by the Data Inspectorate of Norway. 
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Summary of results and general discussion  
1. Increasing numbers of MS births (Paper I) 
The number of births by MS mothers increased markedly during the studied period 
1967-2005. (Figure 1) 
 
 
 
 
 
 
 
In the same time period, the annual number of non-MS births was relatively stable 
and varied between 50,278 (1983) and 68,901 (1969) (Paper I). The incidence rate of 
MS in Hordaland county increased from 1953 and onwards for both men and women, 
(Grytten et al. 2006) but was relatively stable since the early 1980s, illustrated in 
several studies. (Dahl et al. 2004;Grytten et al. 2006;Midgard et al. 1996) Improved 
case finding and diagnostic procedures as well as real changes in risk factors might 
have contributed to the increased incidence rates. (Grytten et al. 2006;Marrie et al. 
2005) Improved diagnostic procedures, including the use of MRI, CSF and 
electrophysiological examinations, improved treatment options, as well as 
improvement of the general health care and neurologic services have given a shorter 
onset-diagnosis interval. (Grytten et al. 2006) This shortening of the time interval 
from clinical MS onset to the diagnosis of MS may also have contributed to the 
increase in registered MS births seen in our data. The patients also have stronger 
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demands to be informed of their diagnosis and possible treatment options by their 
neurologist. Thus, it is reasonable to assume that more women gave birth between 
MS onset and diagnosis during the earlier years covered by our study, and hence are 
not reported in the MBRN to have MS. However, this was not supported by our data 
in Paper III.  
The increasing numbers of births for the whole MS group over time (Paper I) was not 
accompanied by a simultaneous increase in parity for these women. This suggests a 
real increase in the proportion of women with MS who give birth. The last 10 years 
with new disease-modifying treatment and the reassuring findings in several studies 
showing no risk of pregnancy in MS women (Roullet et al. 1993;Weinshenker et al. 
1989b;Worthington et al. 1994) have probably had a substantial, positive impact on 
MS women’s preferences related to pregnancy and birth-giving. These factors have 
led to a change both in patients’ and physicians’ attitudes. The increased numbers of 
MS births is a background characteristic for interpreting our data. Thus time period 
was regarded as a strong confounder for many of our studied variables along with 
changes in obstetric trends. 
 
2. Reduced birth weight in MS births (Paper I-IV) 
Women with MS had a higher frequency of neonates being SGA (13.5 % versus 11.3 
% among references, P=0.003 adjusted for mother’s age and time period) (Paper I). 
The association MS and SGA was even stronger when we compared term births in 
MS to references (OR 1.61, 95 % CI 1.26-2.05, P<0.001 adjusted for mother’s age 
and time period) (Paper I). Reduced mean birth weight (-96g) and length (-0.5cm) for 
the MS neonates (Table in Errata), was in line with this finding. We applied the SGA 
definition that uses data from the MBRN (Skjaerven et al. 2000) to our dataset, and 
excluded plural births, but not infants with malformations, still births and births with 
caesarean section. SGA is associated with caesarean section since conditions that give 
rise to restricted fetal growth, like preeclampsia and congenital malformations, also 
 47
can be indications for a caesarean section. SGA by itself may also be an indication for 
caesarean section. But despite the increase in SGA births in the MS group, no 
negative clinical impact in terms of increased mortality for the MS newborns was 
found. 
 
Since caesarean section may be a result of inadequate fetal growth, we found it not 
appropriate to adjust for caesarean section in the analysis of the association MS and 
birth weight. Instead we excluded births with planned caesarean sections in Paper II. 
However, although equal mean gestational age of the newborns in the MS (281 days) 
and the reference group (282 days) for the planned vaginal deliveries, we found that 
both length (-0.3cm, P=0.04 adjusted for mother’s age) and weight (-108g, P<0.001) 
was reduced in the MS group (Paper II). A possible limitation in this analysis was 
that selection for planned caesarean section might have been different in MS and non-
MS women and thus give rise to selection bias. This problem could arise if the 
threshold was lower for this operative intervention in MS mothers than in healthy 
mothers.  
 
Our results in Paper III indicated that the reduced birth weight in MS was linked to 
manifest disease only. Mean birth weight was 3509g, 3511g and 3428g in the pre MS 
group, the early MS group and the manifest MS group, respectively. Neonates born 
after the MS diagnosis of their mother had 89g (95 % CI 21-157) lower birth weight 
among term births compared to those born before onset of MS (pre MS) (P = 0.046, 
adjusted for gestation in weeks, mother’s age and time period). Naturally none of the 
pre MS and early MS births were reported in the MBRN as MS births, in contrast to 
the manifest MS where the majority of the births (74.7 %) were recorded with MS in 
the MBRN. The mothers in the manifest MS group were consequently known by the 
health professionals to have this disease. This may have resulted in a different 
handling of the birth in the manifest MS group compared to previous births in the 
same women. Women with manifest MS had an increased rate of caesarean section 
(17.2 %) compared to the pre (7.8 %) and early MS (10.5 %) births (Paper III), 
although this was not significant when adjusted for the time period (P=0.68). Our 
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multivariate analysis showed that the reduced gestational age, most likely related to 
the increased rate of caesarean section did not fully explain the lower birth weight in 
the manifest MS group. High numbers of MS births were required to find this modest 
difference in weight. This might explain why previous studies have failed to detect 
the reduction in birth weight. (Confavreux et al. 1998;Worthington et al. 1994)  
A reduction in both birth weight and length in the MS group, in contrast to a normal 
head circumference, indicates that fetal nutrition might have been insufficient during 
pregnancy. Factors that may affect the well-being of the fetus, like infections, 
malformations and chromosomal abnormalities, (Cunningham et al. 2001) were not 
found to be increased in our material. Additional possible explanations for reduced 
fetal growth include maternal disease (co-morbidity), but only inflammatory arthritis 
and urinary tract infection were more frequent in the MS group, and the rate of 
preeclampsia was even lower in the MS group than in the reference group 
(unpublished data, Paper I).  
Fetal growth is influenced by maternal factors like body weight, nutrition and 
smoking. We found the same effect of smoking on birth weight in MS and the 
reference group (Paper IV). However, low numbers cause uncertainty of this finding. 
Regarding low maternal body weight, previous studies of body composition among 
MS patients diverge. (Ghadirian et al. 1998;Lambert et al. 2002;Nortvedt et al. 
2005;Slawta et al. 2003) A reduction in body weight could be due to changed 
metabolism after MS onset or muscle atrophy as a result of reduced mobility. This is 
influenced by duration of the disease. In our study, the mean maternal age (at giving 
birth) was 29.5 years and MS duration from the year of diagnosis to birth was only 
4.5 years in the manifest MS group (Paper III), making a reduced maternal body mass 
index less likely.  
The reduced birth weight of neonates of MS women could also be linked to aspects of 
neurological dysfunction. Bowel, bladder and sexual dysfunction are frequent and 
may be early manifestations of MS. (Crayton et al. 2004;Nortvedt et al. 2007) 
Pregnant MS women had increased frequency of urinary tract infection (Paper I). 
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This indicated affection of pelvic organs, which may have caused suboptimal 
intrauterine conditions and influenced fetal growth. However, other signs of uterine 
insufficiency like an increased rate of preterm birth were not found in the MS group.   
Thus, reduced weight in the MS group could have been due to a combination of 
several factors. Based on our available data, we cannot define the contribution from 
nutrition, body composition or neurological dysfunction. One major limitation is that 
clinical data like pre-pregnancy disability and body mass index (BMI) measurements 
of the birth-giving mothers were not available. However, comparing all term births 
after onset for PPMS versus RRMS, showed that the PPMS group (22 births) had 
279g (95 % CI 62-496) lower mean birth weight than the RRMS group (664 births) 
(P=0.001, adjusted for mother’s age, time period and gestation in weeks) 
(unpublished data, Paper III). Despite rather small numbers this indicated an 
association between MS neurological deficiency in the mother and reduced birth 
weight of the neonate.  
 
3.  Increased rate of operative interventions (Paper I-III) 
In MS births, the mothers had a higher rate of operative interventions (caesarean 
section, forceps, and vacuum extraction) during delivery compared to the reference 
births (OR 2.54; 95 % CI 1.29-1.84, P<0.001) (Paper I).  
The yearly rate of operative interventions for each five year interval in the MS births 
is illustrated (Figure 2). 
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Except for the 2.6 % rate in the early years 1967-75, the caesarean section rate has 
been fluctuating between 10-23 %. During 1991-2002, the mean rate of caesarean 
section was 18.5 % in the MS group versus 13.2 % in the references (P=0.001). The 
increased rate of total operative interventions in the MS births compared to the 
references included an increased rate of forceps use during 1981-1990 (15.3 % in the 
MS group versus 7.4 % in the references, P<0.001), and an increase in caesarean 
section rate in all time periods (Paper I). Data since 1988 illustrated that at least in 
this time period the increase in caesarean section was due to a high number of 
planned procedures, 9.5 % in the MS group versus 4.6 % among references had a 
planned caesarean section, P<0.001, while the rate of emergency caesarean section 
was equal (9.3 % in the MS group versus 8.5 % among references) (unpublished 
numbers Paper I). The increase in operative interventions could reflect both a higher 
rate of complications making operative intervention necessary, and fear of 
complications due to MS in the birth-giving mother. A common indication for a 
planned caesarean section in Norway is previous section, (Kolas et al. 2003) which 
will contribute to maintaining a high caesarean section rate in the MS group. The 
practice of caesarean section has been rather restrictive in Norway, with a rate of 13.5 
% in 2000 versus 15-22 % in similar countries. (Martin et al. 2001;Mayor 
2002;Odlind et al. 2003) This restrictive attitude among the obstetricians in Norway 
has kept the rate low in the general population, which makes it easier to find an 
increased rate in specific risk groups. 
 
We were not able to identify increases in obstetric complications that could account 
for the increase in caesarean section in the MS group. The complication rate in the 
MS group could possibly have been higher if the rate of caesarean section had been 
held at the same level as for the reference population. This was supported by our 
finding of an affected birth process in planned vaginal MS births with an increase in 
the need for induction (P=0.05), and a slower progression of the second stage of labor 
(P=0.06) and more frequent use of forceps (P=0.04) (Paper II). Induction of birth 
included induction both as an initial procedure and also to enhance the labor process, 
and includes the use of prostaglandin, oxytocin and amniotomy. Since slow 
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progression of the second stage of labor was strongly correlated to induction of birth, 
induction was also included as a covariate for the association slow progression of 
second stage of labor and MS. This did not change the association of slow 
progression of second stage of labor and MS (P=0.08) (Paper II). The second stage of 
labor is a physically demanding phase of labor, and symptoms like fatigue, pareses, 
spasms and sensory disturbances that affect extremities and lower abdomen and 
pelvis may interfere in the labor process and increase the need for intervention in this 
patient group. Maternal exhaustion requiring forceps delivery has been suggested to 
be more frequent in mothers with MS. (Davis & Maslow 1992) In contrast to a 
previous report, (Mueller et al. 2002) we did not find an increase in the use of a 
vacuum extractor, however, regional differences in obstetric practice may account for 
diverse findings. The importance of MS-related symptoms for the decision regarding 
operative intervention was supported by the high proportion of planned caesarean 
section.  
The rate of total birth complications and operative interventions did not differ 
between the pre MS, early MS and manifest MS groups (Paper III). This could 
illustrate that the MS women during their whole birth careers have an increased rate 
of operative intervention. Of the 1368 MS women, 982 had 2 or more births, and 5.7 
% of these women had two or more caesarean sections (unpublished data from Paper 
III).  
To what degree the MS diagnosis plays a role when diagnosing complications during 
pregnancy and birth is not known. However, Mueller et al. (Mueller et al. 2002) 
compared non-MS and MS births and their data supported a heightened degree of 
monitoring during the antenatal care in MS cases. The recording of our studied 
variables in the MBRN had very few missing values both in the reference and the MS 
groups, indicating that recording was reasonably independent of maternal diagnosis. 
 
Our data cannot be used to define the need for operative intervention in MS patients, 
or to establish recommendations for such intervention in MS. But as the increase in 
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caesarean section over time did not result in a reduction in the use of forceps and 
vacuum extractor (Paper I and II), our results indicate that both complications and 
need for operative assistance might have been increased if the caesarean section rate 
had been held low in the MS group.  
 
4.  Maternal diseases (Paper I-II) 
Unlike other immune-mediated disorders such as rheumatic disease (Skomsvoll et al. 
2000) and hypothyroidism (Leung et al. 1993) we have found that MS was associated 
with a reduced risk of preeclampsia. The rate of preeclampsia was 1.7 % in MS 
versus 3.6 % in the reference group (P=0.01 adjusted for time period) (unpublished 
data, Paper I). As preeclampsia may develop late in pregnancy, the higher rate of 
planned caesarean section in the MS group could have prevented some cases of very 
late preeclampsia. However, adjustment for planned caesarean section did not change 
the difference in preeclampsia rate. The frequency of preeclampsia in the MS group 
and the reference group were 1.4 % versus 3.2 % in term births and 5.9 % versus 9.2 
% in preterm births. Having MS probably leads to a closer follow-up during 
pregnancy and birth, (Mueller et al. 2002) indicating that the lower frequency of 
preeclampsia in our study was true. How this finding relates to MS is unknown.  
Urinary tract infection was increased in MS mothers during pregnancy (4.0 % versus 
2.4 % among the references, P=0.001 adjusted for mother’s age, Paper I). This 
condition predisposes for pyelonefritis that can lead to other pregnancy and delivery 
complications like preeclampsia, premature delivery, LBW and fetal mortality. (Le et 
al. 2004) Some of these complications can lead to an increased rate of operative 
intervention during birth. This was illustrated by the association of urinary tract 
infection to emergency caesarean section in our data (Paper II).  
There was an increase of inflammatory arthritis (rheumatoid arthritis and ankylosing 
spondylitis) in our MS group (P=0.018 adjusted for mother’s age and time period, 
Paper I). However, the numbers were too small (inflammatory arthritis reported in six 
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births by four different mothers) to relate this to birth outcome (birth weight in 
particular). Co-morbidity has not been supported in the literature. (Somers et al. 
2006) 
 
5.  Medication in pregnant MS women 
Use of medication during pregnancy was reported for 21 % both in the MS and the 
reference group (unpublished data, Paper IV). None of 250 MS mothers giving births 
used any kind of immunomodulatory drugs including corticosteroids during the 
pregnancy (unpublished data, Paper IV). Medication before pregnancy is not 
recorded in the MBRN. 
The frequency of folic acid supplement before pregnancy registered in the MBRN 
was higher in the MS group than in the reference group (unpublished data, Paper IV). 
This can be due to a higher motivation among pregnant MS women to follow up 
recommendations (Tell et al. 1998) regarding health, or a more determined 
recommendation from doctor, midwife or others. As many as 32 % of the MS women 
reported the use of folic acid supplement during pregnancy despite an assumed 
underreporting of vitamin supplements in the MBRN (Annual Report 2003/4 
MBRN).  
Data on folic acid supplement were not included in Paper IV, but were as follows: 
(Table 1) 
Folic acid supplement MS,  % (n) References,  % P-value 
- before pregnancy 14.4 (36/250) 9.8 0.02 
- during pregnancy 32.0 (80/250) 28.7 0.26 
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6.  Smoking in pregnant MS women (Paper IV) 
Our study on smoking among pregnant MS women (Paper IV) showed that smoking 
did not seem to explain the lower birth weight in the MS newborns. We found no 
difference in the smoking rate 1998-2005 during pregnancy between the MS group 
(10.8 %) and the reference group (11.4 %) (P=0.78). The daily number of cigarettes 
among smokers during pregnancy was slightly lower in the MS group (mean 5.7±4.1) 
compared to the references (7.4±4.6) (P = 0.07). We found that smoking affected 
birth weight similarly in the MS and the reference groups (P-value for the interaction 
MS and smoke on birth weight was 0.72). The difference in mean birth weight 
between smokers and non smokers was found to be 291g in the MS group (P=0.10) 
versus 197g in the reference group (P<0.001) (Table 2, Paper IV), the latter 
difference being in accordance with previous data. (Haug et al. 2000) There was no 
difference in the rate of SGA, LBW and preterm births between smoking MS and 
references. However, our group of pregnant MS smokers was rather small (n=27).  
 
A reduction in the smoking rate during 1998-2005 was seen for both groups (29.4 % 
during 1998-9 to 7.7 % in 2004-5 in the MS group versus 19.1 % to 9.7 % in the 
references, respectively. Figure 1, Paper IV). The reduction was more pronounced 
among pregnant MS women (P=0.03 for the interaction MS and time period, adjusted 
for education). The smoking rate among pregnant women in Norway over the years 
1987-1994 fell from 34 % to 22 %. (Eriksson et al. 1996) Our data illustrate that the 
smoking rate in pregnancy has continued to fall. In Finland the smoking frequency 
was unchanged and 15 % in the period 1987-1997. (Jaakkola et al. 2001) This has 
also been the case in England (1992-1997) with a smoking frequency of 25 %. (Owen 
et al. 1998) Other countries have experienced a fall in smoking rates. In the US 
smoking rates among pregnant white women have been falling from 18 % in 1990-94 
to 14.2 % in 1995-1999. (Ananth et al. 2005) In Sweden smoking in early pregnancy 
decreased from 30 % in 1973 to 12 % in 2000. (Odlind et al. 2003) 
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The reason for the stronger fall in smoking rate in the MS group is uncertain. The MS 
population could to a larger extent have been influenced by the information on the 
hazards of smoking, and especially during pregnancy. A national campaign against 
smoking during pregnancy was introduced in 1989, and the study illustrating birth 
weight reduction in smoking versus non smoking mothers in a large Norwegian 
survey (Haug et al. 2000) got a lot of publicity in 2000. Women with chronic diseases 
where environmental factors play a role in the pathogenesis, like MS, could possibly 
be more receptive to health information than healthy women. Slightly more MS 
patients, however not significant, stopped smoking during pregnancy. Higher 
maternal age and higher educational level as seen in the MS group should increase 
the chance of giving up smoking during pregnancy. (Kleinman & Kopstein 
1987;Lindqvist & Aberg 2001). Cigarette smoking is an increasingly negative factor 
for birth weight through pregnancy. (Ohmi et al. 2002) The negative effect of 
smoking on birth weight is partly caused by impaired placental blood flow. (Larsen et 
al. 2002) Stopping or reducing smoking to less than five cigarettes per day has been 
found to protect against growth retardation, LBW and low Apgar score (Raatikainen 
et al. 2007). Elimination of smoking in pregnancy has been estimated to reduce the 
number of SGA cases by 12 %. (Rasmussen & Irgens 2006)  
 
The smoking information was collected through an interview of the birth-giving 
mother when admitted to hospital. There is no reason to believe that MS women 
report their smoking habits differently compared to the reference group, also 
confirmed by the same frequency of births missing this information (14 %) in both 
groups. All of the smoking MS mothers reported the number of cigarettes per day. 
The groups excluded due to missing smoking information were similar in the MS and 
reference group concerning education level. Preterm birth could be one cause of 
missing smoking information. Data from the MBRN illustrates a 116 % higher 
occurrence of still births in women with missing smoking information than in non-
smokers. (www.fhi.no/eway/default.aspx?) However, since the number of missing 
cases in both the MS and the reference group was equal, we do not believe that our 
results are biased regarding the comparisons of smoking effect in the two groups.  
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7.  Adverse birth outcomes (Papers I-IV) 
Paper I illustrated that there was no increased rate of perinatal mortality and birth 
defects in the MS group compared to the references. We found no difference between 
the births in different stages of maternal MS (Paper III). However, the number of 
births in the MS group was too low to observe minor differences for infrequent 
complications. The rate of still birth in Norway was 0.9 % in 2002, the perinatal 
mortality after 22 weeks of gestation was 0.6 % and the rate of total birth defects was 
4.6 % (Annual Report 2001/2 MBRN). The power to detect a doubling in the rate of 
still births in our MS group with 649 births was 51 %. With 1280 births the power 
would have been 80 %. Hence, unless we assume a marked increase in the risk, we 
have low power in all our four studies to detect differences in these adverse birth 
outcomes. Regarding more frequent adverse outcomes, preterm birth was found 
nearly significantly increased in the MS group (7.9 % versus 6.2 % in the references, 
P=0.07) (Paper I). However, after excluding planned caesarean sections (Paper II) 
there was no longer any such difference (P=0.25). There was no increase in the rate 
of LBW in the MS newborns (Paper I). Thus, our data supports previous studies that 
did not find any adverse birth outcomes in MS women. (Achiron et al. 
2004;Confavreux et al. 1998;Sadovnick et al. 1994) 
 
8.  Recommended obstetric strategy for pregnant MS mothers 
Our data illustrate the overall safety regarding birth-giving in MS women. The 
reduced birth weight in the MS group did not seem to have any negative effect on the 
general health of the newborn. We do not have any reasons to recommend more 
operative interventions in the MS group.  
Births by MS women are affected by a reduction in mean birth weight and an 
increase of SGA, in addition to an increased rate of induction of birth, second stage of 
labour and forceps assistance in planned vaginal births. The two latter findings might 
justify the increased rate of planned caesarean section. However, since we lack 
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clinical data on the mother we cannot link our results on delivery and birth to MS 
severity. Several MS-related symptoms and findings like fatigue and muscular 
extremity, abdominal and perineal weakness and spasticity may cause the slow 
progression of the second stage of labor and increase the need for operative 
assistance. One should be aware that urinary tract infection in this patient group 
increases the risk of operative delivery. Prior to the birth, a clinical assessment of all 
MS women should be made bearing in mind symptoms and signs that can influence 
the birth such as fatigue, paresis, spasticity and urinary tract infection. However, 
present recommendations for pregnancy and obstetric strategies for MS mothers do 
not differ much from those for healthy women. 
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Methodological considerations 
Study design 
All studies presented in this thesis were designed as historical cohort studies. To 
evaluate the internal validity and precision in our studies, we have addressed 
systematic and random error in the MBRN and the MS Registry. Internal validity 
depends on lack of systemic error (selection bias, information bias and confounding). 
Selection bias comes about when the association between exposure and outcome 
differs for those who participate and those who do not participate in the study. 
Information bias can occur if there are errors in measurement or classification of the 
participants in the study. Confounding is discussed under Statistics. 
 
MBRN 
Selection bias 
For most purposes, we have used the entire birth cohorts in the MBRN during the 
specified time period and made comparisons between the MS group and all other 
births. Due to the record linkage with Statistics Norway, the ascertainment of births 
in Norway in the MBRN is close to 100 %. This registry is population based and we 
can assume a negligible selection bias in those studies where MBRN was the only 
source of information (Papers I and IV). In Paper II, we excluded women with 
planned caesarean section from the analyses. This was done in order to evaluate 
whether MS women who were selected to a vaginal delivery had a risk of 
complications during delivery or operative delivery that differed from women 
without MS selected to a vaginal delivery. Even if MS women in this study had an 
equal or higher risk of complications during delivery or operative delivery compared 
to women without MS, differences between the two studied groups may not 
necessarily imply that such differences exist between the MS and the reference 
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populations in general. However, our goal in Paper II was not to describe risks in the 
overall MS population, but to describe risks among those MS patients selected for a 
vaginal delivery.  
Information bias 
Any misclassification or reduced ascertainment of the MS diagnosis in the MBRN 
will weaken the internal validity of the study. Ascertainment of the MS diagnosis in 
the MBRN will depend on diagnostics of MS in general, to what extent her diagnosis 
is recorded in her antenatal record, and to what extent a mother with MS informs 
about the disease when asked during delivery. As discussed in the introduction of this 
thesis, the MS diagnostic criteria have changed during the years 1967-2002. The 
Poser criteria (1983) which included CSF examination, and even more importantly 
the McDonald criteria (2001) which additionally included MRI of the brain, both 
allowed an earlier diagnosis. This has resulted in a shortening of the time interval 
between MS onset and MS diagnosis. (Grytten et al. 2006;Marrie et al. 2005) This 
allows more of the women’s births to take place after the MS diagnosis. Whether or 
not maternal diagnoses are recorded, will not depend on birth outcome, since 
maternal diagnoses in general are reported prior to delivery (from the mother or the 
standard form filled in during pregnancy by the patient’s physician), at admittance to 
the hospital. Since the neurological record does not follow the pregnant women, the 
information on the MS diagnosis is exclusively dependent on information from the 
mother, the attending physician or the midwife. 
 
In our historical cohort, 461 MS women (Paper I) gave birth during a 36 year period, 
with MS mothers representing 0.04 % of all the mothers. The incidence of MS in 
Norway has gradually increased, but has remained stable on around 8 per 100,000 
during the last 20-25 years, (Celius & Vandvik 2001;Dahl et al. 2004;Gronning et al. 
1991;Grytten et al. 2006) of which 2/3 will be women. MS prevalence in Hordaland 
County January 1 2003 for women aged 18-45 years was 152/100,000. (Grytten et al. 
2006)  
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Validation of the MS diagnosis as given in the MBRN has not been done. In our 
Paper III, linking of the MS women from the MS Registry to the MBRN revealed that 
75 % of the 308 births during the first year after the diagnosis MS, were confirmed 
reported with the diagnosis MS in MBRN (the MS registry is considered the 
“goldstandard” with a high positive predictive value of the MS diagnosis). For each 
year after the diagnosis, the frequency of MS mothers that had their MS diagnosis 
(from the MS Registry) recorded also in the MBRN, increased. Five years after the 
MS diagnosis 84 % of the births were noted as MS in the MBRN. The MS group in 
the MBRN may possibly be constituted by the more affected cases since a smaller 
proportion of those with recent MS diagnosis are missed in the MBRN. An increasing 
load of symptoms and disability of MS increase the possibility for the mother to 
inform about the diagnosis or the diagnosis to be evident to the attending midwife or 
doctor. This may lead to an over-estimation of the effects of MS (using the MS 
diagnoses recorded in the MBRN) in our study. 
 
A high number of false positive MS births in our material would have diluted any 
effects. A sensitivity of 88.2 % for rheumatic disease (Skomsvoll et al. 2002) and a 
positive predictive value of 98.8 % for myasthenia gravis (Hoff et al. 2007) have 
been reported in the MBRN. Linking consecutive births showed that the MS 
diagnosis was highly consistent (Paper I). In only 9.8 % of the 461 MS mothers the 
information on MS diagnosis was missing, after MS was first noted in one, two or 
three consecutive births. Although some of these cases may represent false-positive 
cases, part of this may be due to clinical remission. MS is a well-defined and specific 
disease, well known to both doctors, midwifes and patients. In addition, MS is a type 
of disease that usually influences family planning. All these factors increase the MS 
sensitivity and specificity in MBRN. In all Papers, a few MS births were probably 
included in the (non-MS) reference group (false negatives). But since the reference 
group is large, the false negatives will have hardly any dilutive effect on the risk 
estimates. 
 
Smoking information in MBRN 
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We assume that women with a chronic disease like MS give accurate smoking 
information to the MBRN to the same degree as the reference group. The smoking 
information was collected at admission to hospital, and therefore before an eventually 
complicated birth with a negative birth outcome. The recall bias is considered low. 
This direct interview could, however, have resulted in under-reporting either by 
denial of smoking or by refusing to give information. Giving information on smoking 
habits was optional for the women. Fourteen percent of all birth-giving mothers chose 
not to give smoking information, equal in the MS and the reference group, suggesting 
that MS women did not have a different attitude to reporting smoking habits. Since 
the same proportion of births lack smoking information in the MS and the reference 
group, excluding these from the analysis of smoking frequency and birth weight will 
probably not give biased results regarding the comparisons between MS and non-MS. 
Of the 250 MS women included, only 27 smoked at the end of the pregnancy. This 
group is treated as if they smoked during the entire pregnancy.  
   
Norwegian MS Registry 
Selection bias 
Ascertainment of MS cases in the MS Registry at the time of linkage between the two 
registries was estimated to only about 50 % (May 2005). Since the neurologists 
tended to report recently diagnosed cases, the Registry had a predominance of newly 
compared to formerly diagnosed cases. The reporting is done mostly by the treating 
neurologist, so we would suspect a slightly higher proportion of patients with 
immunotherapy and frequent follow-ups included, which means those with more 
active disease. Expanded disability status scale (EDSS) score is not registered. 
Immunomodulatory treatment was not used by any of the MS women during 
pregnancy. The reporting to the MS registry was geographically skewed since some 
hospitals had reported only a minority of their patients. However, this should not bias 
our results.  
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The proportion of MS subtype, mean age at onset and gender proportions indicate 
that the MS registry population is a representative population of MS patients. 
Female:male ratio in the MS Registry in 2005 was 2.1:1 and the frequency of RRMS 
was 84 %, similar to what is found in Norwegian epidemiological studies and in other 
Western populations. The patients must consent to register, and one could speculate 
that factors like social status, education and MS severity would influence the patients’ 
willingness to register.  
 
Eighty-six percent of the women in the MS Registry gave a positive written response 
to our approach. The consenting versus the non-consenting women were comparable 
for frequency of RRMS (89.8 % versus 88.5 %) and mean age at MS diagnosis 
(32.6±9.8 versus 32.1±9.0). In Paper III, the records of all the female patients in the 
MS registry were linked to the MBRN. Due to the start of registration in the MBRN, 
MS women who gave birth prior to 1967 were not included. 1371 of the 1755 
consenting women had births registered in the time period 1967-2002. With a mean 
maternal age for giving birth between 26.2 years in 1967 and 29.4 years in 2002 and 
MS onset most commonly between the ages of 20 and 40 years, the majority of births 
occur prior to the MS diagnosis. This was illustrated in our study comparing births in 
different stages of MS. 
 
Information bias 
The definition of MS onset was the year when their first MS related symptom 
occurred, with the neurologist interpreting the patient history. Validation of MS 
diagnosis given in the MS Registry has not been done. However, specificity is 
considered high – only neurologists report to the registry, using the McDonald 
criteria. (McDonald et al. 2001;Myhr et al. 2006). From the start of registrations in 
2001 and until 2005 (the whole period that is relevant for our study) the same criteria 
for MS have been used. In 1960-70, before disease-modifying treatment was 
introduced, some avoidance to give the women the MS diagnosis could have lead to 
women not knowing that they had the diagnosis even if they fulfilled the diagnostic 
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criteria. If such cases were included in our study, this could have lead to 
underestimation of the MS effects.  
 
A certain misclassification of MS has been revealed in autopsy studies, and according 
to data from the Danish Multiple Sclerosis Registry the diagnosis definite MS was in 
a clinical and pathoanatomical study correct in 94 % of the cases. (Engell 1988) The 
comparison of the validity of MS from the Danish to the Norwegian MS Registry can 
not automatically be done due to different ways of classifying the diagnosis 
according to the different criteria. (Fangerau et al. 2004) Compared to the Danish 
Multiple Sclerosis Registry (duration of 40 years) with a completeness of the 
Registry estimated to be high, probably about 90 %, (Koch-Henriksen & Hyllested 
1988) completeness of the Norwegian MS Registry (duration 4 years) is still not 
satisfying.  
 
The categorization of births in Paper III was: births before year of debut; births in the 
year of debut or later, but before the year of diagnosis; birth in the year of diagnosis 
or later. A MS flare-up postpartum can be both first symptom and precipitate the MS 
diagnosis. This may lead to a wrong categorization. By categorizing births in the 
group with the assumed highest risk, we minimized the risk of overestimating any 
association.  
 
The period from MS onset to MS diagnosis has become shorter in recent years. 
(Grytten et al. 2006;Marrie et al. 2005) Since our historical cohort comprises births 
from 1967, we could assume that there will be a relatively larger population of birth-
giving MS mothers who gave birth between onset and diagnosis in the first part of the 
period, but fewer women in the last years. This was not supported in our data (Table 
I, Paper III). Particular for this group (early MS) was that they have MS but without 
the women or the obstetrician being aware of the developing neurological disease 
during pregnancy and birth. From an immunological point of view, it might be more 
correct to compare before and after the clinical onset of MS only. This was done for 
birth weight analyses.  
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Precision 
High precision implies lack of random errors. For our epidemiological research this 
includes especially sampling errors. The smaller the study group and the rarer the 
studied outcomes are, the more the normal variation in the study population will 
affect the ability to detect differences between groups. Power analyses can yield 
information on the strength of the data to find measured differences as significant. 
Power-estimations for the associations between smoking and pregnancy outcomes 
according to MS status are implemented since birth defects and perinatal mortality 
are low frequency unfavorable birth outcomes. The power was 30 % to detect a 
perinatal mortality rate among MS smokers of 3.7 % versus 1.0 % among reference 
smokers as different. For 5-min Apgar <7 and preterm birth the power to detect a 
difference of the observed magnitude was 17.9 % and 6.8 % respectively. We also 
presented power to detect a difference of the observed magnitude in models of birth 
weight analysis (Papers III and IV). 
 
External validity 
External validity implies an evaluation of to what degree the results and conclusions 
obtained from our data are valid also for other MS populations. The external validity 
is strongly dependent on the internal validity. Our results would have had higher 
validity if the MS Registry had an ascertainment close to 100 %. Due to the extensive 
time period examined, the selection of MS women who give birth will differ due to 
changing attitudes towards birth-giving in MS women. This selection may also differ 
between countries, partly due to social welfare benefits. An advantage of conducting 
an epidemiological study like this in Norway is the relatively homogenous population 
both genetically and socially. We have examined a large group of MS patients, and a 
large and unselected reference group, which is important for the high external 
validity. Thus, there is reason to believe that the results should be applicable to all 
populations of white women in countries with similar health care system and 
treatment of MS prior to and during pregnancy. 
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Multiple testing 
The issue of how MS affects pregnancy, delivery and birth outcome is studied on an 
open basis, evaluating many different possible associations. Therefore our study 
(especially Papers I and II) can be viewed as explorative and hypothesis generating 
rather than hypothesis testing. Both the choice of methods and the interpretation of 
results must be viewed in this context. A broad range of possible associations 
between MS and pregnancy, delivery and birth outcome risks exists. With a 5 % 
significance level and given no effect of the exposure studied, one out of 20 studied 
associations will fall out positive in the long run. Statistical methods, like Bonferroni 
correction, (Altman 1991) to adjust for multiple testing can be valuable if one has a 
pre-defined set of associations. Such statistical corrections have been implemented in 
studies of candidate gene regions in MS patients. (Datta et al. 2007) The value of 
adjusting for multiple testing is debated, and one objection is that it is too 
conservative and one may miss real differences. (Bland & Altman 1995;Perneger 
1998) In that case the null hypothesis is maintained even if the alternative hypothesis 
is correct (type II error). Due to the explorative design of the study, we have not 
adjusted for multiple testing. If we had a situation with a large number of significant 
associations the method for correction would more likely be used. In our study only a 
few significant associations were found and the findings were associated with each 
other, like an increased rate of SGA together with a decrease in birth weight and 
length. The most important task for our study was to investigate the risk of 
complications during pregnancy and birth for the MS women, and identify potential 
risk factors. Associations found need to be verified in future studies.  
Assumption of independence 
The statistical methods that we have used are based on the assumption of 
independence between the observations. In the analyses of birth data where women 
may give birth more than once, the data cannot be regarded as independent. While so 
far only a limited number of studies that use birth registry data have used statistical 
procedures that account for such dependency, the use of such methods will probably 
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be more common as more statistical program packages develop and implement the 
necessary procedures. In general, not accounting for dependent data will result in 
standard errors estimated too small, leading to confidence intervals that are too 
narrow and p-values that are too small. However, to the degree that birth data are 
stratified for birth order, data will not be dependent. Parity was not a significant 
confounder for the association MS and caesarean section.  
Limitations and advantages 
The MS Registry will be of greater importance as the ascertainment increases in 
coming years. However, the lack of clinical data is the one major disadvantage with 
both MBRN and the MS Registry. Clinical neurological data at the time of pregnancy 
could have been obtained through a clinical prospective study, or retrieved from 
hospital records. One indirect measurement of disease activity would be disease 
activity measured on MRI in birth-giving MS women. In this way MRI could be 
applied to compare pregnancy, delivery and birth outcome to CNS inflammation. 
Studies where disease severity can be linked to delivery and birth outcome can reveal 
if there is any subgroup of MS women at special risk. Thus, the correlation between 
MS disability and the pregnancy, delivery and birth outcome is a major challenge for 
further studies.  
 
Effects of the exposure of disease-modifying drugs used during pregnancy on the 
pregnancy, delivery and newborn could not be undertaken in our study due to the 
lack of mothers taking such drugs. In the future, there will possibly be some 
pregnancies where the MS mother has used disease-modifying drugs, and effects of 
this exposure can be evaluated comparing with MS birth without such exposure.  
 
The main advantage of our study is the nationwide population based design that 
enables us to find target groups of satisfactory size. Large size target groups are 
important especially for infrequent outcomes. Also, data used in the study are 
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retrieved from two registries with well defined procedures for collection and 
recording of the information. 
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Conclusions  
The results of our epidemiological study underline the overall safety and the good 
outcome of pregnancy and delivery in MS women.  
Still, our study demonstrates an impact of MS on pregnancy, delivery and the 
newborn. We found that mothers with MS have an increased risk of operative 
delivery and especially planned caesarean section. Delivery was affected in the 
subgroup of MS mothers with planned vaginal births. MS affected the neonate 
prenatally with a reduced birth weight but without resulting birth defects or increased 
mortality. Our study of births in the different stages of MS suggests that manifest MS 
in birth-giving mothers seems to affect birth weight, and this might indicate a relation 
to the neurological dysfunction in this patient group rather than genetic or 
constitutional factors. Smoking did not seem to explain the lower birth weight found 
for the neonates of MS mothers.  
A clinical assessment should be made prior to birth bearing in mind symptoms that 
can protract or complicate the birth for the MS woman such as fatigue, paresis, 
spasticity and chronic urinary tract infection.  
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Errata 
Table 3 in Paper I presents means of the neonates’ characteristics retrieved from the 
adjusted analyses. The correct table below includes observed means and adjusted 
differences in mean. 
Table 3 Characteristics of the neonates  
 MS  Controls Difference 
in mean 
Adjusted 
difference 
in mean 
p Value 
Sex, % boys 49.0 51.4   0.22 
Mean gestational age, days 277.5 280.4 2.9 1.8 0.018* 
Preterm (<37 weeks of 
gestation), % 
7.9 6.2   0.07 
Mean length, cm 49.6 50.1 0.5 0.4 0.003† 
Mean birth-weight, g 3391 3487 96 123 <0.001* 
Mean head circumference, 
cm 
35.1 35.2 0.1 0.07 0.39* 
Low birth-weight 
(<2500g),  % 
4.9 5.2   0.76 
High birth-weight 
(≥4500g), % 
2.3 3.5   0.014* 
Small for gestational age, 
%‡ 
13.5 11.3   0.003* 
*p Adjusted for mother’s age and time period.† p Adjusted for time period. ‡Singleton births 
at gestational age 28 to 44 weeks for the years 1967 to 2002, according to the standards for 
gestational age in single births for the years 1987 to 1998 in Norway. 
 
 70 
References 
 
Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, & Achiron R (2004). 
Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-
related relapses in multiple sclerosis. J Neurol 251: 1133-1137. 
Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, & Wiendl H (2007). 
Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: 
relevance of natural killer cells. Clin Exp Immunol 151: 235-243. 
Al-Shammri S, Rawoot P, Azizieh F, AbuQoora A, Hanna M, Saminathan TR, & 
Raghupathy R (2004). Th1/Th2 cytokine patterns and clinical profiles during and 
after pregnancy in women with multiple sclerosis. J Neurol Sci 222: 21-27. 
Altman DG (1991). Practical statistics for medical research. London: Chapman & 
Hall/CRC. 
Ananth CV, Kirby RS, & Kinzler WL (2005). Divergent trends in maternal cigarette 
smoking during pregnancy: United States 1990-99. Paediatr Perinat Epidemiol 19: 
19-26. 
Ananth CV & Platt RW (2004). Reexamining the effects of gestational age, fetal 
growth, and maternal smoking on neonatal mortality. BMC Pregnancy Childbirth 4: 
22. 
Ascherio A & Munger KL (2007a). Environmental risk factors for multiple sclerosis. 
Part I: the role of infection. Ann Neurol 61: 288-299. 
Ascherio A & Munger KL (2007b). Environmental risk factors for multiple sclerosis. 
Part II: Noninfectious factors. Ann Neurol 61: 504-513. 
Bader AM, Hunt CO, Datta S, Naulty JS, & Ostheimer GW (1988). Anesthesia for 
the obstetric patient with multiple sclerosis. J Clin Anesth 1: 21-24. 
Bennett KA (2005). Pregnancy and multiple sclerosis. Clin Obstet Gynecol 48: 38-
47. 
Bergsjoe, P., Maltau, J. M., Molne, K., & Nesheim, B.-I. Obstetrikk.  1993.  
Universitetsforlaget AS.  
Bettes BA, Coleman VH, Zinberg S, Spong CY, Portnoy B, DeVoto E, & Schulkin J 
(2007). Cesarean delivery on maternal request: obstetrician-gynecologists' 
knowledge, perception, and practice patterns. Obstet Gynecol 109: 57-66. 
 71
Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, 
McFarland H, Henkart PA, & Martin R (2006). Regulatory CD56(bright) natural 
killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy 
(daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 103: 5941-5946. 
Black C, Kaye JA, & Jick H (2005). Cesarean delivery in the United Kingdom: time 
trends in the general practice research database. Obstet Gynecol 106: 151-155. 
Bland JM & Altman DG (1995). Multiple significance tests: the Bonferroni method. 
BMJ 310: 170. 
Boskovic R, Wide R, Wolpin J, Bauer DJ, & Koren G (2005). The reproductive 
effects of beta interferon therapy in pregnancy: a longitudinal cohort. Neurology 65: 
807-811. 
Bronnum-Hansen H, Koch-Henriksen N, & Stenager E (2004). Trends in survival 
and cause of death in Danish patients with multiple sclerosis. Brain 127: 844-850. 
Cabre P (2007). Migration and multiple sclerosis: the French West Indies experience. 
J Neurol Sci 262: 117-121. 
Celius EG & Vandvik B (2001). Multiple sclerosis in Oslo, Norway: prevalence on 1 
January 1995 and incidence over a 25-year period. Eur J Neurol 8: 463-469. 
Chaouat G (2007). The Th1/Th2 paradigm: still important in pregnancy? Semin 
Immunopathol 29: 95-113. 
Cohen EN (1968). Distribution of local anesthetic agents in the neuraxis of the dog. 
Anesthesiology 29: 1002-1005. 
Compston A & Coles A (2002). Multiple sclerosis. Lancet 359: 1221-1231. 
Compston, A. & Confavreux, C. 2006, "The distribution of multiple sclerosis," in 
McAlpine's Multiple Sclerosis, 4 edn, A. Compston et al., eds., Churchill Livingstone 
Elsevier, London, pp. 69-105. 
Confavreux, C. & Compston, A. 2006, "The natural history of multiple sclerosis," in 
McAlpine's Multiple Sclerosis, 4 edn, A. Compston et al., eds., Churchill Livingstone 
Elsevier, London, pp. 183-272. 
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, & Moreau T 
(1998). Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple 
Sclerosis Group. N Engl J Med 339: 285-291. 
Confavreux C & Vukusic S (2006). Natural history of multiple sclerosis: a unifying 
concept. Brain 129: 606-616. 
 72 
Confavreux C, Vukusic S, & Adeleine P (2003). Early clinical predictors and 
progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 
126: 770-782. 
Costenbader KH & Karlson EW (2006). Cigarette smoking and autoimmune disease: 
what can we learn from epidemiology? Lupus 15: 737-745. 
Coyle PK, Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, Lynn J, Weinstock-
Guttman B, & Pardo L (2004). Multiple sclerosis gender issues: clinical practices of 
women neurologists. Mult Scler 10: 582-588. 
Crayton H, Heyman RA, & Rossman HS (2004). A multimodal approach to 
managing the symptoms of multiple sclerosis. Neurology 63 (suppl 5): 12-18. 
Cunningham FG, Gant NF, Leveno KJ, Gilstrap III LC, Hauth JC, & Wenstrom KD 
(2001). Williams Obstetrics, 21st ed. McGraw-Hill, Medical Publishing Division. 
Dahl OP, Aarseth JH, Myhr KM, Nyland H, & Midgard R (2004). Multiple sclerosis 
in Nord-Trondelag County, Norway: a prevalence and incidence study. Acta Neurol 
Scand 109: 378-384. 
Damek DM & Shuster EA (1997). Pregnancy and multiple sclerosis. Mayo Clin Proc 
72: 977-989. 
Datta P, Harbo HF, Ryder LP, Akesson E, Benedikz J, Celius EG, Andersen O, Myhr 
KM, Sandberg-Wollheim M, Hillert J, Svejgaard A, Sorensen PS, Spurkland A, & 
Oturai A (2007). A follow-up study of Nordic multiple sclerosis candidate gene 
regions. Mult Scler 13: 584-589. 
Davis RK & Maslow AS (1992). Multiple sclerosis in pregnancy: a review. Obstet 
Gynecol Surv 47: 290-296. 
De las Heras V, de Andrés C, Téllez N, & Tintoré M (2007). Pregnancy in multiple 
sclerosis patients treated with immunomodulators prior to or during part of the 
pregnancy: a descriptive study in the Spanish population. Mult Scler 13: 981-984. 
Dean G & Elian M (1997). Age at immigration to England of Asian and Caribbean 
immigrants and the risk of developing multiple sclerosis. J Neurol Neurosurg 
Psychiatry 63: 565-568. 
Drake E, Drake M, Bird J, & Russell R (2006). Obstetric regional blocks for women 
with multiple sclerosis: a survey of UK experience. Int J Obstet Anesth 15: 115-123. 
Drew PD & Chavis JA (2000). Female sex steroids: effects upon microglial cell 
activation. J Neuroimmunol 111: 77-85. 
 73
Durufle A, Petrilli S, Nicolas B, Robineau S, Guille F, Edan G, & Gallien P (2006). 
Effects of pregnancy and child birth on urinary symptoms and urodynamics in 
women with multiple sclerosis. Int Urogynecol J 17: 352-355. 
Ebers GC (2005). A twin consensus in MS. Mult Scler 11: 497-499. 
Ebers GC, Sadovnick AD, & Risch NJ (1995). A genetic basis for familial 
aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature. 377: 
150-151. 
Eckerlund I & Gerdtham UG (1999). Estimating the effect of cesarean section rate on 
health outcome. Evidence from Swedish hospital data. Int J Technol Assess Health 
Care 15: 123-135. 
Engell T (1988). A clinico-pathoanatomical study of multiple sclerosis diagnosis. 
Acta Neurol Scand 78: 39-44. 
Ericson A, Gunnarskog J, Kallen B, & Otterblad-Olausson P (1991). Surveillance of 
smoking during pregnancy in Sweden, 1983-1987. Acta Obstet Gynecol Scand 70: 
111-117. 
Eriksson KM, Salvesen KA, Haug K, & Eik-Nes SH (1996). Smoking habits among 
pregnant women in a Norwegian county 1987-1994. Acta Obstet Gynecol Scand 75: 
355-359. 
Fangerau T, Schimrigk S, Haupts M, Kaeder M, Ahle G, Brune N, Klinkenberg K, 
Kotterba S, Mohring M, & Sindern E (2004). Diagnosis of multiple sclerosis: 
comparison of the Poser criteria and the new McDonald criteria. Acta Neurol Scand 
109: 385-389. 
Ferrero S, Esposito F, Pretta S, & Ragni N (2006). Fetal risks related to the treatment 
of multiple sclerosis during pregnancy and breastfeeding. Expert Rev Neurother 6: 
1823-1831. 
Ferrero S, Pretta S, & Ragni N (2004). Multiple sclerosis: management issues during 
pregnancy. Eur J Obstet Gynecol Reprod Biol 115: 3-9. 
Friend KB, Mernoff ST, Block P, & Reeve G (2006). Smoking rates and smoking 
cessation among individuals with multiple sclerosis. Disabil Rehabil 28: 1135-1141. 
Garcia MA & Blasco MR (2007). Confirming the MS diagnosis. Int MS J 14: 58-63. 
Ghadirian P, Dadgostar B, Azani R, & Maisonneuve P (2001). A case-control study 
of the association between socio-demographic, lifestyle and medical history factors 
and multiple sclerosis. Can J Public Health 92: 281-285. 
 74 
Ghadirian P, Jain M, Ducic S, Shatenstein B, & Morisset R (1998). Nutritional 
factors in the aetiology of multiple sclerosis: a case-control study in Montreal, 
Canada. Int J Epidemiol 27: 845-852. 
Gronlie SA, Myrvoll E, Hansen G, Gronning M, & Mellgren SI (2000). Multiple 
sclerosis in North Norway, and first appearance in an indigenous population. J 
Neurol 247: 129-133. 
Gronning M, Riise T, Kvale G, Nyland H, Larsen JP, & Aarli JA (1991). Incidence of 
multiple sclerosis in Hordaland, western Norway: a fluctuating pattern. 
Neuroepidemiology 10: 53-61. 
Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, & Myhr KM (2006). A 50-
year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway. 
Neurology 66: 182-186. 
Haas J & Hommes OR (2007). A dose comparison study of IVIG in postpartum 
relapsing-remitting multiple sclerosis. Mult Scler 13: 900-908. 
Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager PL, de Bakker PI, 
Gabriel SB, Mirel DB, Ivinson AJ, Pericak-Vance MA, Gregory SG, Rioux JD, 
McCauley JL, Haines JL, Barcellos LF, Cree B, Oksenberg JR, & Hauser SL (2007). 
Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 
357: 851-862. 
Hager RM, Daltveit AK, Hofoss D, Nilsen ST, Kolaas T, Oian P, & Henriksen T 
(2004). Complications of cesarean deliveries: rates and risk factors. Am J Obstet 
Gynecol 190: 428-434. 
Hale TW (2006). Medications and Mothers' Milk. 12 edn. Amarillo: Hale Publishing. 
Hannah ME, Hannah WJ, Hewson SA, Hodnett ED, Saigal S, & Willan AR (2000). 
Planned caesarean section versus planned vaginal birth for breech presentation at 
term: a randomised multicentre trial. Term Breech Trial Collaborative Group. Lancet 
356: 1375-1383. 
Haug K, Irgens LM, Skjaerven R, Markestad T, Baste V, & Schreuder P (2000). 
Maternal smoking and birthweight: effect modification of period, maternal age and 
paternal smoking. Acta Obstet Gynecol Scand 79: 485-489. 
Hayes CE, Nashold FE, Spach KM, & Pedersen LB (2003). The immunological 
functions of the vitamin D endocrine system. Cell Mol Biol 49: 277-300. 
Heiberg EE & Helsing E (1995). Changes in breastfeeding practices in Norwegian 
maternity wards: national surveys 1973, 1982 and 1991. Acta Paediatr 84: 719-724. 
Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, & Jick H (2005). 
Cigarette smoking and the progression of multiple sclerosis. Brain 128: 1461-1465. 
 75
Hoff JM, Daltveit AK, & Gilhus NE (2003). Myasthenia gravis: consequences for 
pregnancy, delivery, and the newborn. Neurology 61: 1362-1366. 
Hoff JM, Daltveit AK, & Gilhus NE (2007). Myasthenia gravis in pregnancy and 
birth: identifying risk factors, optimising care. Eur J Neurol 14: 38-43. 
Houtchens MK (2007). Pregnancy and multiple sclerosis. Semin Neurol 27: 434-441. 
Jaakkola N, Jaakkola MS, Gissler M, & Jaakkola JJ (2001). Smoking during 
pregnancy in Finland: determinants and trends, 1987-1997. Am J Public Health 91: 
284-286. 
Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer 
JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, 
Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, 
Mass MK, Munschauer FE, III, Priore RL, Pullicino PM, Scherokman BJ, Whitham 
RH, & . (1996). Intramuscular interferon beta-1a for disease progression in relapsing 
multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). 
Ann Neurol 39: 285-294. 
Jansson L & Holmdahl R (1998). Estrogen-mediated immunosuppression in 
autoimmune diseases. Inflamm Res 47: 290-301. 
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, 
Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, & Wolinsky JS (1998). 
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its 
clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 
Multiple Sclerosis Study Group. Neurology 50: 701-708. 
Kallen K (2001). The impact of maternal smoking during pregnancy on delivery 
outcome. Eur J Public Health 11: 329-333. 
Kantarci O & Wingerchuk D (2006). Epidemiology and natural history of multiple 
sclerosis: new insights. Curr Opin Neurol 19: 248-254. 
Kappos L (2004). Effect of drugs in secondary disease progression in patients with 
multiple sclerosis. Mult Scler 10 Suppl 1: discussion S54-5.: S46-S54. 
Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban 
X, Barkhof F, Radu EW, Bauer L, Dahms S, Lanius V, Pohl C, & Sandbrink R 
(2007). Effect of early versus delayed interferon beta-1b treatment on disability after 
a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of 
the BENEFIT study. Lancet 370: 389-397. 
Kleinman JC & Kopstein A (1987). Smoking during pregnancy, 1967-80. Am J 
Public Health 77: 823-825. 
 76 
Koch-Henriksen N & Hyllested K (1988). Epidemiology of multiple sclerosis: 
incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple 
Sclerosis Registry. Acta Neurol Scand 78: 369-380. 
Kolas T, Hofoss D, Daltveit AK, Nilsen ST, Henriksen T, Hager R, Ingemarsson I, & 
Oian P (2003). Indications for cesarean deliveries in Norway. Am J Obstet Gynecol 
188: 864-870. 
Kolas T, Saugstad OD, Daltveit AK, Nilsen ST, & Oian P (2006). Planned cesarean 
versus planned vaginal delivery at term: comparison of newborn infant outcomes. Am 
J Obstet Gynecol 195: 1538-1543. 
Korn-Lubetzki I, Kahana E, Cooper G, & Abramsky O (1984). Activity of multiple 
sclerosis during pregnancy and puerperium. Ann Neurol 16: 229-231. 
Kramer MS, Olivier M, McLean FH, Dougherty GE, Willis DM, & Usher RH 
(1990). Determinants of fetal growth and body proportionality. Pediatrics 86: 18-26. 
Kumar AR, Hale TW, & Mock RE (2000). Transfer of interferon alfa into human 
breast milk. J Hum Lact 16: 226-228. 
Lambert CP, Lee AR, & Evans WJ (2002). Body composition in ambulatory women 
with multiple sclerosis. Arch Phys Med Rehabil 83: 1559-1561. 
Larsen LG, Clausen HV, & Jonsson L (2002). Stereologic examination of placentas 
from mothers who smoke during pregnancy. Am J Obstet Gynecol 186: 531-537. 
Le J, Briggs GG, McKeown A, & Bustillo G (2004). Urinary tract infections during 
pregnancy. Ann Pharmacother 38: 1692-1701. 
Leung AS, Millar LK, Koonings PP, Montoro M, & Mestman JH (1993). Perinatal 
outcome in hypothyroid pregnancies. Obstet Gynecol 81: 349-353. 
Liestol K, Rosenberg M, & Walloe L (1988). Breast-feeding practice in Norway 
1860-1984. J Biosoc Sci 20: 45-58. 
Lindqvist R & Aberg H (2001). Who stops smoking during pregnancy? Acta Obstet 
Gynecol Scand 80: 137-141. 
Lundmark F, Duvefelt K, Iacobaeus E, Kockum I, Wallstrom E, Khademi M, Oturai 
A, Ryder LP, Saarela J, Harbo HF, Celius EG, Salter H, Olsson T, & Hillert J (2007). 
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple 
sclerosis. Nat Genet 39: 1108-1113. 
Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, & Vollmer T (2005). 
Changes in the ascertainment of multiple sclerosis. Neurology 65: 1066-1070. 
 77
Martin JA, Hamilton BE, & Ventura SJ (2001). Births: preliminary data for 2000. 
Natl Vital Stat Rep 49: 1-20. 
Mayor S (2002). Caesarean section rate in England reaches 22%. BMJ 324: 1118. 
McCourt C, Weaver J, Statham H, Beake S, Gamble J, & Creedy DK (2007). 
Elective cesarean section and decision making: a critical review of the literature. 
Birth 34: 65-79. 
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, 
McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley 
W, Thompson A, van den NS, Weinshenker BY, & Wolinsky JS (2001). 
Recommended diagnostic criteria for multiple sclerosis: guidelines from the 
International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127. 
McFarland HF & Martin R (2007). Multiple sclerosis: a complicated picture of 
autoimmunity. Nat Immunol 8: 913-919. 
Menacker F, Declercq E, & Macdorman MF (2006). Cesarean delivery: background, 
trends, and epidemiology. Semin Perinatol 30: 235-241. 
Midgard R, Riise T, Svanes C, Kvale G, & Nyland H (1996). Incidence of multiple 
sclerosis in More and Romsdal, Norway from 1950 to 1991. An age-period-cohort 
analysis. Brain 119: 203-211. 
Mikaeloff Y, Caridade G, Tardieu M, & Suissa S (2007). Parental smoking at home 
and the risk of childhood-onset multiple sclerosis in children. Brain 130: 2589-2595. 
Miller DH (2004). Biomarkers and surrogate outcomes in neurodegenerative disease: 
lessons from multiple sclerosis. NeuroRx 1: 284-294. 
Moster D, Lie RT, & Markestad T (1999). Relation between size of delivery unit and 
neonatal death in low risk deliveries: population based study. Arch Dis Child Fetal 
Neonatal Ed 80: F221-F225. 
Mueller BA, Zhang J, & Critchlow CW (2002). Birth outcomes and need for 
hospitalization after delivery among women with multiple sclerosis. Am J Obstet 
Gynecol 186: 446-452. 
Munger KL, Levin LI, Hollis BW, Howard NS, & Ascherio A (2006). Serum 25-
hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296: 2832-2838. 
Munger KL, Zhang SM, O'Reilly E, Hernan MA, Olek MJ, Willett WC, & Ascherio 
A (2004). Vitamin D intake and incidence of multiple sclerosis. Neurology 62: 60-
65. 
Myhr KM, Grytten N, Aarseth JH, & Nyland H (2006). The Norwegian Multiple 
Sclerosis National Competence Centre and National Multiple Sclerosis registry -- a 
 78 
resource for clinical practice and research. Acta Neurol Scand 113 (suppl 183): 37-
40. 
Myhr KM, Riise T, Vedeler C, Nortvedt MW, Gronning R, Midgard R, & Nyland HI 
(2001). Disability and prognosis in multiple sclerosis: demographic and clinical 
variables important for the ability to walk and awarding of disability pension. Mult 
Scler 7: 59-65. 
Nelson LM, Franklin GM, & Jones MC (1988). Risk of multiple sclerosis 
exacerbation during pregnancy and breast-feeding. JAMA 259: 3441-3443. 
Nilsen ST, Daltveit AK, & Irgens LM (2001). [Obstetric departments, delivery units 
and births in Norway in the 1990s]. Tidsskr Nor Laegeforen 121: 3208-3212. 
Nortvedt MW, Riise T, Frugard J, Mohn J, Bakke A, Skar AB, Nyland H, Glad SB, 
& Myhr KM (2007). Prevalence of bladder, bowel and sexual problems among 
multiple sclerosis patients two to five years after diagnosis. Mult Scler 13: 106-112. 
Nortvedt MW, Riise T, & Maeland JG (2005). Multiple sclerosis and lifestyle factors: 
the Hordaland Health Study. Neurol Sci 26: 334-339. 
Odlind V, Haglund B, Pakkanen M, & Otterblad OP (2003). Deliveries, mothers and 
newborn infants in Sweden, 1973-2000. Trends in obstetrics as reported to the 
Swedish Medical Birth Register. Acta Obstet Gynecol Scand 82: 516-528. 
Ohmi H, Hirooka K, & Mochizuki Y (2002). Fetal growth and the timing of exposure 
to maternal smoking. Pediatr Int 44: 55-59. 
Ostensen M & Villiger PM (2007). The remission of rheumatoid arthritis during 
pregnancy. Semin Immunopathol 29: 185-191. 
Owen L, McNeill A, & Callum C (1998). Trends in smoking during pregnancy in 
England, 1992-7: quota sampling surveys. BMJ 317: 728. 
Paavilainen T, Kurki T, Parkkola R, Farkkila M, Salonen O, Dastidar P, Elovaara I, 
& Airas L (2007). Magnetic resonance imaging of the brain used to detect early post-
partum activation of multiple sclerosis. Eur J Neurol 14: 1216-1221. 
Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, Friesen 
MH, Jacobson S, Kasapinovic S, Chang D, av-Citrin O, Chitayat D, Nulman I, 
Einarson TR, & Koren G (2000). Birth defects after maternal exposure to 
corticosteroids: prospective cohort study and meta-analysis of epidemiological 
studies. Teratology 62: 385-392. 
Perneger TV (1998). What's wrong with Bonferroni adjustments. BMJ 316: 1236-
1238. 
 79
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, 
Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, & 
Sandrock AW (2006). A randomized, placebo-controlled trial of natalizumab for 
relapsing multiple sclerosis. N Engl J Med 354: 899-910. 
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, 
Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, 
Weinshenker BG, & Wolinsky JS (2005a). Diagnostic criteria for multiple sclerosis: 
2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846. 
Polman CH, Wolinsky JS, & Reingold SC (2005b). Multiple sclerosis diagnostic 
criteria: three years later. Mult Scler 11: 5-12. 
Pons JC, Lebon P, Frydman R, & Delfraissy JF (1995). Pharmacokinetics of 
interferon-alpha in pregnant women and fetoplacental passage. Fetal Diagn Ther 10: 
7-10. 
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson 
KP, Sibley WA, Silberberg DH, & Tourtellotte WW (1983). New diagnostic criteria 
for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231. 
Poser S & Poser W (1983). Multiple sclerosis and gestation. Neurology 33: 1422-
1427. 
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a 
Subcutaneously in Multiple Sclerosis (1998). Randomised double-blind placebo-
controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. 
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a 
Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352: 1498-1504. 
Raatikainen K, Huurinainen P, & Heinonen S (2007). Smoking in early gestation or 
through pregnancy: a decision crucial to pregnancy outcome. Prev Med 44: 59-63. 
Rasmussen S & Irgens LM (2006). The effects of smoking and hypertensive 
disorders on fetal growth. BMC Pregnancy Childbirth 6: 16. 
Riise T, Nortvedt MW, & Ascherio A (2003). Smoking is a risk factor for multiple 
sclerosis. Neurology 61: 1122-1124. 
Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, & Marteau 
R (1993). Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent 
patients. J Neurol Neurosurg Psychiatry 56: 1062-1065. 
Runmarker B & Andersen O (1995). Pregnancy is associated with a lower risk of 
onset and a better prognosis in multiple sclerosis. Brain 118: 253-261. 
 80 
Sadovnick AD, Eisen K, Hashimoto SA, Farquhar R, Yee IM, Hooge J, Kastrukoff L, 
Oger JJ, & Paty DW (1994). Pregnancy and multiple sclerosis. A prospective study. 
Arch Neurol 51: 1120-1124. 
Saito S (2000). Cytokine network at the feto-maternal interface. J Reprod Immunol 
47: 87-103. 
Salemi G, Callari G, Gammino M, Battaglieri F, Cammarata E, Cuccia G, D'Amelio 
M, Lupo I, Ragonese P, & Savettieri G (2004). The relapse rate of multiple sclerosis 
changes during pregnancy: a cohort study. Acta Neurol Scand 110: 23-26. 
Sanchez-Ramon S, Navarro AJ, Aristimuno C, Rodriguez-Mahou M, Bellon JM, 
Fernandez-Cruz E, & de AC (2005). Pregnancy-induced expansion of regulatory T-
lymphocytes may mediate protection to multiple sclerosis activity. Immunol Lett 96: 
195-201. 
Sandberg-Wollheim M, Frank D, Goodwin TM, Giesser B, Lopez-Bresnahan M, 
Stam-Moraga M, Chang P, & Francis GS (2005). Pregnancy outcomes during 
treatment with interferon beta-1a in patients with multiple sclerosis. Neurology 65: 
802-806. 
Sawcer S, Ban M, Maranian M, Yeo TW, Compston A, Kirby A, Daly MJ, De Jager 
PL, Walsh E, Lander ES, Rioux JD, Hafler DA, Ivinson A, Rimmler J, Gregory SG, 
Schmidt S, Pericak-Vance MA, Akesson E, Hillert J, Datta P, Oturai A, Ryder LP, 
Harbo HF, Spurkland A, Myhr KM, Laaksonen M, Booth D, Heard R, Stewart G, 
Lincoln R, Barcellos LF, Hauser SL, Oksenberg JR, Kenealy SJ, & Haines JL (2005). 
A high-density screen for linkage in multiple sclerosis. Am J Hum Genet 77: 454-
467. 
Schwendimann RN & Alekseeva N (2007). Gender issues in multiple sclerosis. Int 
Rev Neurobiol 79: 377-392. 
Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, Rieckmann P, Selmaj 
K, Visser LH, & Sorensen PS (2005). EFNS guideline on treatment of multiple 
sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis 
relapses. Eur J Neurol 12: 939-946. 
Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, 
Andreoni L, Trivedi P, Salvetti M, Faggioni A, & Aloisi F (2007). Dysregulated 
Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 204: 2899-
2912. 
Sibley WA, Bamford CR, Clark K, Smith MS, & Laguna JF (1991). A prospective 
study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 54: 
584-589. 
 81
Sicotte NL, Liva SM, Klutch R, Pfeiffer P, Bouvier S, Odesa S, Wu TC, & Voskuhl 
RR (2002). Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann 
Neurol 52: 421-428. 
Skjaerven R, Gjessing HK, & Bakketeig LS (2000). Birthweight by gestational age in 
Norway. Acta Obstet Gynecol Scand 79: 440-449. 
Skomsvoll J, Ostensen M, Baste V, & Irgens L (2002). Validity of a rheumatic 
disease diagnosis in the Medical Birth Registry of Norway. Acta Obstet Gynecol 
Scand 81: 831-834. 
Skomsvoll JF, Ostensen M, Irgens LM, & Baste V (2000). Pregnancy complications 
and delivery practice in women with connective tissue disease and inflammatory 
rheumatic disease in Norway. Acta Obstet GynecolScand 79: 490-495. 
Slawta JN, Wilcox AR, McCubbin JA, Nalle DJ, Fox SD, & Anderson G (2003). 
Health behaviors, body composition, and coronary heart disease risk in women with 
multiple sclerosis. Arch Phys Med Rehabil 84: 1823-1830. 
Smaill F & Hofmeyr GJ (2002). Antibiotic prophylaxis for cesarean section. 
Cochrane.Database.Syst.Rev.: CD000933. 
Somers EC, Thomas SL, Smeeth L, & Hall AJ (2006). Autoimmune diseases co-
occurring within individuals and within families: a systematic review. Epidemiology 
17: 202-217. 
Steinman RM & Nussenzweig MC (2002). Avoiding horror autotoxicus: the 
importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 
99: 351-358. 
Takahashi T & Sakaguchi S (2003). The role of regulatory T cells in controlling 
immunologic self-tolerance. Int Rev Cytol 225: 1-32. 
Tell GS, Vollset SE, Lande B, Pedersen JI, Loken EB, & Jacobsen BK (1998). 
[Folate and health--new knowledge and new recommendation]. Tidsskr Nor 
Laegeforen 118: 3155-3160. 
The IFNB Multiple Sclerosis Study Group (1995). Interferon beta-1b in the treatment 
of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB 
Multiple Sclerosis Study Group and The University of British Columbia MS/MRI 
Analysis Group. Neurology 45: 1277-1285. 
Thompson DS, Nelson LM, Burns A, Burks JS, & Franklin GM (1986). The effects 
of pregnancy in multiple sclerosis: a retrospective study. Neurology 36: 1097-1099. 
Thrower BW (2007). Clinically isolated syndromes: predicting and delaying multiple 
sclerosis. Neurology 68: S12-S15. 
 82 
Torkildsen O, Grytten N, & Myhr KM (2007). Immunomodulatory treatment of 
multiple sclerosis in Norway. Acta Neurol Scand Suppl 187: 46-50. 
Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, & Bo L (1998). Axonal 
transection in the lesions of multiple sclerosis. N Engl J Med 338: 278-285. 
Tremlett HL & Oger J (2008). Ten years of adverse drug reaction reports for the 
multiple sclerosis immunomodulatory therapies: a Canadian perspective. Mult Scler 
14: 94-105. 
Trooster WJ, Teelken AW, Gerrits PO, Lijnema TH, Loof JG, Minderhoud JM, & 
Nieuwenhuis P (1996). The effect of gonadectomy on the clinical course of chronic 
experimental allergic encephalomyelitis. Clin Neurol Neurosurg 98: 222-226. 
Trooster WJ, Teelken AW, Kampinga J, Loof JG, Nieuwenhuis P, & Minderhoud JM 
(1993). Suppression of acute experimental allergic encephalomyelitis by the synthetic 
sex hormone 17-alpha-ethinylestradiol: an immunological study in the Lewis rat. Int 
Arch Allergy Immunol 102: 133-140. 
Turner AP, Kivlahan DR, Kazis LE, & Haselkorn JK (2007). Smoking among 
veterans with multiple sclerosis: prevalence correlates, quit attempts, and unmet need 
for services. Arch Phys Med Rehabil 88: 1394-1399. 
van den Broek HH, Damoiseaux JG, De Baets MH, & Hupperts RM (2005). The 
influence of sex hormones on cytokines in multiple sclerosis and experimental 
autoimmune encephalomyelitis: a review. Mult Scler 11: 349-359. 
van Walderveen MA, Tas MW, Barkhof F, Polman CH, Frequin ST, Hommes OR, & 
Valk J (1994). Magnetic resonance evaluation of disease activity during pregnancy in 
multiple sclerosis. Neurology 44: 327-329. 
van Wijk I, de Hoon AC, Jurhawan R, Tjoa ML, Griffioen S, Mulders MA, van Vugt 
JM, & Oudejans CB (2000). Detection of apoptotic fetal cells in plasma of pregnant 
women. Clin Chem 46: 729-731. 
Veiby G, Daltveit AK, & Gilhus NE (2007). Pregnancy, delivery and perinatal 
outcome in female survivors of polio. J Neurol Sci 258: 27-32. 
Viisainen K, Gissler M, Hartikainen AL, & Hemminki E (1999). Accidental out-of-
hospital births in Finland: incidence and geographical distribution 1963-1995. Acta 
Obstet Gynecol Scand 78: 372-378. 
von Rango U (2008). Fetal tolerance in human pregnancy-A crucial balance between 
acceptance and limitation of trophoblast invasion. Immunol Lett 115: 21-32. 
Voskuhl RR (2003). Hormone-based therapies in MS. Int MS J 10: 60-66. 
 83
Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, 
Confavreux C, & The Pregnancy In Multiple Sclerosis Group (2004). Pregnancy and 
multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. 
Brain 127: 1353-1360. 
Wegmann TG, Lin H, Guilbert L, & Mosmann TR (1993). Bidirectional cytokine 
interactions in the maternal-fetal relationship: is successful pregnancy a TH2 
phenomenon? Immunol Today 14: 353-356. 
Weinshenker BG (1996). Epidemiology of multiple sclerosis. Neurol Clin 14: 291-
308. 
Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, & 
Ebers GC (1989a). The natural history of multiple sclerosis: a geographically based 
study. I. Clinical course and disability. Brain 112: 133-146. 
Weinshenker BG, Hader W, Carriere W, Baskerville J, & Ebers GC (1989b). The 
influence of pregnancy on disability from multiple sclerosis: a population-based 
study in Middlesex County, Ontario. Neurology 39: 1438-1440. 
Wilczynski JR, Kalinka J, & Radwan M (2008). The role of T-regulatory cells in 
pregnancy and cancer. Front Biosci 13: 2275-2289. 
Worthington J, Jones R, Crawford M, & Forti A (1994). Pregnancy and multiple 
sclerosis--a 3-year prospective study. J Neurol 241: 228-233. 
Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, 
Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jager HR, & 
Clifford DB (2006). Evaluation of patients treated with natalizumab for progressive 
multifocal leukoencephalopathy. N Engl J Med 354: 924-933. 
Zenclussen AC, Schumacher A, Zenclussen ML, Wafula P, & Volk HD (2007). 
Immunology of pregnancy: cellular mechanisms allowing fetal survival within the 
maternal uterus. Expert Rev Mol Med 9: 1-14. 
 
 
